Protein-polymer conjugation by reductive amination of aldehyde-functionalised polymers

The reductive amination of aldehyde-functionalised oligonucleotides in low salt conditions addresses the challenges of controlling labeling in protein-oligonucleotide conjugates, enhancing efficiency and reproducibility, and simplifying the bioconjugation process for applications like FRET-based immunoassays.

WO2026238469A1PCT designated stage Publication Date: 2026-11-19MEDICQUANT APS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/062772
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-04
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing bioconjugation methods for protein-oligonucleotide conjugates face challenges in controlling the number of modifications, require labor-intensive procedures, and lack reproducibility, especially in maintaining the drug-to-antibody ratio, while also being costly and complex.

Method used

A process involving reductive amination of aldehyde-functionalised polymers, specifically oligonucleotides, is used to conjugate proteins like antibodies in low salt concentrations, allowing for controlled mono- or double-labeling without the need for templating DNA, using reducing agents like NaCNBH4, and optimizing reaction conditions.

Benefits of technology

This method achieves efficient and reproducible protein-oligonucleotide conjugates with controlled labeling, improving yield and reducing procedural complexity, suitable for applications like competitive immunoassays using FRET.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026062772_19112026_PF_FP_ABST
    Figure EP2026062772_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a process for providing protein-polymer conjugates, preferably protein-oligonucleotide conjugates. In particular, the present invention relates to a process for preparing antibody-oligonucleotide conjugates comprising at the most 1-2 oligonucleotides per antibody. Such conjugates are particularly suitable for competitive immunoassays for the determination of the concentration of small molecule drugs in solution by FRET.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 83692PC01

[0002] 1

[0003] PROTEIN-POLYMER CONJUGATION BY REDUCTIVE AMINATION OF ALDEHYDE-FUNCTIONALISED POLYMERS

[0004] Technical field of the invention

[0005] The present invention relates to a process for preparing protein-polymer conjugates, preferably protein-oligonucleotide conjugates. In particular, the present invention relates to a process for preparing antibody-oligonucleotide conjugates comprising at the most 1-2 oligonucleotides per protein, such as antibodies or small molecule binding proteins. Such conjugates are suitable for competitive immunoassay for determination of the concentration of small molecule drugs in solution by FRET.

[0006] Background of the invention

[0007] Bioconjugation, a field that is instrumental in research and development, diagnostics, biopharmaceuticals, and imaging, relies heavily on bioconjugates. Among these, DNA-protein conjugates are particularly significant. They offer a unique means to identify, functionalise, or manipulate proteins, a critical aspect of bioanalytical chemistry, molecular diagnostics, and nanotechnology. However, the production and application of these conjugates present several challenges.

[0008] A primary concern is the control over the number of modifications. The process is further complicated by the use of costly reagents, labour-intensive procedures, and complex purification methods. Moreover, maintaining control over the drug-to-antibody ratio, ensuring reproducibility, yield, and upholding quality control pose significant challenges.

[0009] To address these issues, various strategies have been developed. Recombinant protein engineering is one such strategy that provides excellent reproducibility and control over modifications. It facilitates a variety of conjugation chemistries and sites. However, this method necessitates a comprehensive understanding of protein structure and involves a labour-intensive process that requires substantial optimisation, leading to prolonged development timelines.

[0010] Conversely, global labelling enables the straightforward introduction of a range of commercially available labels. This method is an efficient way to generate83692PC01

[0011] 2

[0012] conjugates, requiring minimal insight into proteins. However, it provides limited control over the drug-to-antibody ratio, reproducibility, and modification site, and there is a risk of losing or altering protein function due to modification.

[0013] Site-directed conjugation offers a compromise between the extremes of recombinant and global approaches. It provides some control over the modification site, the number of labels, and the amount of lab work required. Typically, methods that yield a single conjugate product necessitate genetically engineered proteins, while those that use wild-type proteins inevitably result in a product mixture. Consequently, the choice often lies between a more laborious recombinant protein expression strategy and a heterogeneous product mixture. Skovsgaard et al. discloses a method for achieving some control of site selectivity by guiding a benzaldehyde-modified oligonucleotide to an antibody using aptamer techniques. The method described uses a DNA templating strategy and high concentrations of salt during the conjugation process.

[0014] W02016005474 Al discloses site-selective conjugation of an oligonucleotide conjugate or a small molecule to a metal-binding protein. W02016005474 Al uses a DNA templating strategy and high concentrations of salt during the conjugation process.

[0015] WO2020173822 Al discloses the detection and quantification of small molecules where protein-DNA conjugates are formed using a templated strategy in high salt. US 2022 / 137034 Al discloses oligonucleotide-protein conjugates used for FRET. US 2013 / 184184 Al discloses antibody-oligonucleotide conjugates used for FRET. Hence, an improved bioconjugation method with less demand to reagent complexity, less laborious procedures that exhibit a larger degree of control would be advantageous, and, in particular, a more efficient and / or reliable method to controllable label one or two oligonucleotides per protein would be advantageous.

[0016] Summary of the invention

[0017] The inventing team for the present invention has realised that specific aldehyde-modified polymers (preferably oligonucleotides) can be efficiently conjugated to proteins, preferably antibodies, in the absence of a templating DNA strand and in a low salt concentration with significant control over the number of conjugates per83692PC01

[0018] 3

[0019] protein, where the dominant species are mono-labelled (DAR=1) or doublelabelled (DAR=2) when employing reductive amination conditions e.g. presence of a reductive agent.

[0020] Without being bound by theory, it is believed that the negative charge of singlestranded DNA provides adherence to the protein under low salt concentration (low ionic strength). The term "low salt", may be considered to below 250 mM, preferably equal to or below 100 mM, even more preferably equal to or below 50 mM, and even more preferably equal to or below 10 mM or being free or substantially free of salt, such as NaCI. As shown in the example section, lowering salt concentration improves conjugation and in particular levels of mono-labelled (DAR=1) proteins.

[0021] Again, without being bound by theory, it is believed that the negative charge of polymers, such as DNA, furthermore increases the energy barrier for further iminium ion formations of other aldehyde-modified DNA strands and, therefore, lowers the likelihood of multiple labels.

[0022] It has also been found that for certain antibodies, the presence of a Cy3 modification on the DNA strand can improve the coupling efficiency. Again, without being bound by theory, it is considered that Cy3 may mimic the antibody target (such as Dabigatran or Apixaban) or, in other ways, exhibit affinity towards the antibody, thereby improving coupling efficiency at a relevant position, e.g. when used in a competitive immunoassay, such as outlined in WO2020173822 Al.

[0023] Lastly, it has also been found that for certain antibodies, the presence of the small molecule target of the antibody during bioconjugation influences bioconjugation yield (Dabigatran fab fragment sees a decrease in the presence of the small target molecule, anti-apixaban antibody sees an increase in the presence of the small molecule target). Again, without being bound by theory, it is considered that the binding site plays a role in the bioconjugation reaction.

[0024] Thus, an object of the present invention relates to the provision of an improved process for conjugating oligonucleotides to proteins, in particular to antibodies.

[0025] In particular, it is an object of the present invention to provide a process for conjugating oligonucleotides to proteins that solves the above-mentioned83692PC01

[0026] 4

[0027] problems of the prior art with the need for templating DNA and complex coupling processes.

[0028] Thus, one aspect of the invention relates to a process for preparing a protein-oligonucleotide conjugate (1); the process comprising the steps of:

[0029] a) providing a protein (2), preferably an antibody or fragment thereof;

[0030] b) providing an oligonucleotide (3), preferably a DNA oligonucleotide, the oligonucleotide comprising

[0031] i. an aldehyde moiety (4), preferably being a 4-formylbenzoate moiety, preferably the aldehyde moiety being coupled via the 3'-end of the oligonucleotide; and

[0032] c) mixing the protein (2) from step a) with the oligonucleotide (3) from step b) in the presence of a reducing agent, preferably NaCNBHs, and wherein the total salt concentration in the mixture is below 400 mM; d) incubating the mixture from step c), such as for at least 5 minutes at a temperature in the range of 3-45°C; and

[0033] e) providing a composition comprising covalently linked protein- oligonucleotide conjugates (1).

[0034] Another aspect of the present invention relates to a protein-oligonucleotide conjugate (1) obtained by or obtainable by the process according to the invention.

[0035] Yet another aspect of the present invention relates to the use of a protein-oligonucleotide conjugate (1) according to the invention in a competitive immunoassay, such as for the detection of small molecule drugs in solution by FRET, such as based on an antibody-oligonucleotide-donor dye and a competitive binder-oligonucleotide-acceptor dye.

[0036] Example 2 shows that the method of the invention can efficiently produce DAR=1 and DAR=2 protein-DNA conjugates for a range of proteins and fragments thereof. For Fab fragments, only DAR=1 was obtained.

[0037] Example 3 shows that 1) Presence of the small molecule (dabigatran) reduces bioconjugation to a dabigatran targeting antibody; 2) Absence of Cy3 on the DNA strand reduces bioconjugation; and 3) the presence of high salt concentrations reduces bioconjugation.83692PC01

[0038] 5

[0039] Example 4 shows that increased equivalency of benzaldehyde-modified DNA resulted in increased yield of the protein DNA conjugate.

[0040] Example 5 shows that the presence of free Cy3 in the reaction mixture has an antagonistic effect on the yield, indicating that Cy3 on the DNA strand has a positive effect on bioconjugation (see example 3).

[0041] Example 6 shows again that high salt (MgC ) lowers bioconjugation.

[0042] Example 7 shows that the presence of salt significantly lowers the yield of the bioconjugation reaction.

[0043] Example 8 shows that the method of the invention is applicable to a wide range of antibodies.

[0044] Example 9 shows that the method of the invention is applicable to a wide range of proteins different from antibodies.

[0045] Example 10 shows that the bioconjugation favours water-stable reducing agents that are selective for reductive amination, affording the conjugate in up to 53% isolated yield.

[0046] Brief description of the figures

[0047] Figure 1

[0048] Figure 1 illustrates a specific embodiment of the process of the invention, wherein a protein (2) reacts with an oligonucleotide (3) modified with an aldehyde moiety (4) to form a protein-oligonucleotide conjugate (1) (Protein, DNA and small molecules are not in scale).

[0049] The present invention will now be described in more detail in the following.

[0050] Detailed description of the invention

[0051] Definitions

[0052] Prior to discussing the present invention in further detail, the following terms and conventions will first be defined:

[0053] Small molecules

[0054] In the present context, the term "small molecule" relates to a low molecular weight (< or = 900 daltons) organic compound that may regulate a biological process, with a size on the order of 1 nm. Most drugs are small molecules. Larger83692PC01

[0055] 6

[0056] o c structures, such as nucleic acids and proteins, and many polysaccharides are not v> small molecules. T Cs In an embodiment, the small molecules have a size in the range 100-900, 200-900, 300-900, 400-900 or 430-900 Daltons.

[0057] Examples of small molecules according to the invention are listed in Table 1 below.

[0058] Table 1: Examples of small molecules

[0059] ^=7

[0060] Compound Structure of the targets the antibody(ies) Example have been raised to show affinity for.

[0061] Dabigatran

[0062] W

[0063] / \ \= / Z / X / IXJ X I n

[0064] Apixaban NH2

[0065] 0=== /

[0066] \ JI KI -n-y o

[0067] O °

[0068] dCH3y y

[0069] CO UJ

[0070] Rivaroxaban 2, 7, 8 n A / =\ X A ° \JXaX^ / " XX\X°

[0071] Edoxaban 2, 8

[0072]

[0073] 83692PC01

[0074]

[0075] Antibody

[0076] The term "antibody", as used herein, refers to a protein of the immunoglobulin (Ig) superfamily that binds non-covalently to certain substances (antigens / analytes) to form an antibody-antigen / analyte complex. Antibodies can be endogenous or polyclonal, wherein an animal is immunised to elicit a polyclonal antibody response or by recombinant methods resulting in monoclonal antibodies produced from hybridoma cells or other cell lines. It is understood that the term "antibody", as used herein, includes within its scope any of the various classes or sub-classes of immunoglobulin derived from any of the animals conventionally used.

[0077] Antibody fragments

[0078] The term "antibody fragments", as used herein, refers to fragments of antibodies that retain the principal selective binding characteristics of the whole antibody. Particular fragments are well-known in the art, for example, Fab, Fab', and F(ab')2, which are obtained by digestion with various proteases, pepsin or papain, and which lack the Fc fragment of an intact antibody or the so-called "halfmolecule" fragments obtained by reductive cleavage of the disulfide bonds connecting the heavy chain components in the intact antibody. Such fragments also include isolated fragments consisting of the light-chain-variable region, "Fv" fragments consisting of the variable regions of the heavy and light chains, and recombinant single-chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker. Other examples of binding fragments include (i) the Fd fragment, consisting of the VH and CHI domains; (ii) the dAb fragment, which consists of a VH domain; (iii) isolated CDR regions; and (iv)83692PC01

[0079] 8

[0080] single-chain Fv molecules (scFv) described above. In addition, arbitrary fragments can be made using recombinant technology that retains antigen-recognition characteristics.

[0081] Analyte

[0082] The term "analyte" as used herein refers to any entity that an analyte binding protein has affinity for.

[0083] Analyte binding protein

[0084] The term "analyte binding protein" as used herein refers to a protein that has affinity for a discrete epitope, antigen or analyte that can be used with the methods of the present invention. Preferably, the analyte binding protein is an antibody or fragment thereof. In another preferred embodiment, the analyte binding protein is the endogenous target (biological target) for a small molecule, or an analyte binding fragment or derivative thereof.

[0085] Affinity

[0086] The term "affinity", as used herein, refers to the strength of the binding interaction of two molecules, such as an antibody and its antigen (or the analyte binding protein and the analyte / analyte analogue according to the invention). For bivalent molecules such as antibodies, affinity is typically defined as the binding strength of one binding domain for the antigen, e.g. one Fab fragment for the antigen. The binding strength of both binding domains together for the antigen is referred to as "avidity". As used herein, "high affinity" refers to a ligand that binds to an antibody having an affinity constant (Ka) greater than 104M’1, typically 105- 1011M’1; as determined by inhibition ELISA or an equivalent affinity determined by comparable techniques such as, for example, Scatchard plots or using Kd / dissociation constant, which is the reciprocal of the Ka, etc.

[0087] Ionic strength

[0088] The ionic strength of a solution is a measure of the concentration of ions in that solution. The molar ionic strength, I, of a solution is a function of the concentration of all ions present in that solution. In the present context, "ionic strength" is determined using the formula83692PC01

[0089] n

[0090]

[0091] 2_1

[0092] Ci is the molar concentration of ion i (M, mol / L), zi is the charge number of that ion, and the sum is taken over all ions in the solution. For a 1:1 electrolyte such as sodium chloride, where each ion is singly-charged, the ionic strength is equal to the concentration. For the electrolyte MgSO4, however, each ion is double charged, leading to an ionic strength that is four times higher than an equivalent concentration of sodium chloride.

[0093] A nuance here is that the molar ionic strength parameter does not take into account the charge density of the ions, with Mg2+ions having a higher charge density than Na+ions. This is related to the HSAB theory, where the degree of interaction is also, to some extent, dictated by the charge density, which in this context can partly explain why Mg2+is often more potent in shielding oxygen in the phosphate backbone of DNA compared to Na+. The stabilisation effect of magnesium ion on the DNA duplex is, in literature, about 140 times larger than that of sodium ion, and cations are at least 20 times more potent in stabilising DNA duplex compared to NaCI. The effect observed here is therefore anticipated to be partly based on the ionic strength formula, but also on the stronger interaction of divalent cations with DNA (Nucleic Acids Research, 1999, Vol. 27, No. 14 2957-2965).

[0094] Water soluble

[0095] In the present context the term "Water soluble", e.g. as used herein in relation to a reducing agent, means that the reducing agent is capable of dissolving in water or an aqueous reaction medium at a concentration sufficient to permit effective reduction under the reaction conditions, preferably at a concentration of at least 0.01 g / L, more preferably at least 0.1 g / L, without precipitation that materially interferes with the reduction reaction. For example, NaCNBHs is considered water soluble.83692PC01

[0096] 10

[0097] Aqueous-compatible

[0098] In the present context the term "Aqueous compatible", e.g. as used herein in relation to a reducing agent, means effective in an aqueous or aqueous-organic reaction medium. 2-Methylpyridine borane complex (2-picoline borane) is considered aqueous compatible.

[0099] In one embodiment, the reducing agent is water soluble, such as being NaCNBHs. In another embodiment, the reducing agent is aqueous-compatible, such as being 2-Methylpyridine borane complex.

[0100] Metal binding protein

[0101] The term "metal binding protein" as used herein is a protein or a metalloprotein that can bind a metal ion. The term "metal binding protein" may be used interchangeably with the term "metalloprotein". In metal binding protein or metalloproteins, metal ions are coordinated at the metal binding site. The metal ion coordinated by the metal binding protein can for example be selected from the group consisting of Fe(ll), Fe(lll), Cu(ll), Cu(l), Zn(ll), Mg(ll), Ca(ll), V(lll), Co(ll), Co(lll), Ni(ll), Ni(lll), Cd(l), Cd(ll), Mo(IV), Mo(VI), Sn(ll) and Sn(IV).

[0102] The metal binding protein comprises a metal binding site. The metal binding site is usually nitrogen, oxygen or sulfur centers belonging to amino acid residues of the protein. Virtually all amino acid residues can participate in coordinating the metal ion. The metal binding site may be a histidine cluster. The histidine cluster may comprise at least 2 histidine residues, such as for example at least 3 histidine residues, such as at least 4 histidine residues or such as for example at least 5 histidine residues. The metal binding site may naturally be occurring in the metal binding protein, wherein the metal binding protein can be either a mutant or a wild type protein. Thus, the metal binding site may not be comprised in or a part of an artificial amino acid sequence that has been fused to the protein by recombinant DNA technology, such as for example a tag or a histidine tag that has been fused to the protein.

[0103] The metal binding protein may be selected from the group consisting of metalloenzymes and signal-transduction metalloproteins. The metal binding protein may be a metal binding glycoprotein, such as for example transferrin.83692PC01

[0104] 11

[0105] In an embodiment of the invention, the protein is not a metal binding protein. As previously outlined, the process of the invention does not rely on a DNA templating technique nor that the protein is metal binding as e.g. outlined in WO2020173822 Al. Hence, the process of the invention is more versatile.

[0106] Process for preparing a protein-DNA conjugate

[0107] The present invention relates to a process for protein-DNA conjugates. Thus, an aspect of the invention relates to a process for preparing a protein-oligonucleotide conjugate (1); the process comprising the steps of:

[0108] a) providing a protein (2), preferably an antibody or fragment thereof; b) providing an oligonucleotide (3), preferably a DNA oligonucleotide, the oligonucleotide comprising

[0109] i. an aldehyde moiety (4), preferably being a 4-formylbenzoate moiety, preferably the aldehyde moiety being coupled via the 3'-end of the oligonucleotide; and

[0110] c) mixing the protein (2) from step a) with the oligonucleotide (3) from step b) in the presence of a reducing agent, preferably NaCNBHs, and wherein the total salt concentration in the mixture is below 400 mM; d) incubating the mixture from step c), such as for at least 5 minutes at a temperature in the range of 3-45°C; and

[0111] e) providing a composition comprising covalently linked protein- oligonucleotide conjugates (1).

[0112] As outlined in the example section, it can be seen that high salt has a negative impact on the conjugation yield (see e.g. examples 3, 5, 6 and 7).

[0113] In an broader aspect the invention relates to a process for preparing a protein-polymer conjugate (1); the process comprising the steps of:

[0114] a) providing a protein (2), preferably an antibody or fragment thereof; b) providing a polymer (3), preferably a polyelectrolyte, more preferably an oligonucleotide, and even more preferably a DNA oligonucleotide, the polymer comprising

[0115] i. an aldehyde moiety (4), preferably being a 4-formylbenzoate moiety; and

[0116] c) mixing the protein (2) from step a) with the polymer (3) from step b) in the presence of a reducing agent, preferably NaCNBHs, and83692PC01

[0117] 12

[0118] wherein the total salt concentration in the mixture is below 400 mM; d) incubating the mixture from step c), such as for at least 5 minutes at a temperature in the range of 3-45 °C; and

[0119] e) providing a composition comprising covalently linked protein-polymer conjugates (1).

[0120] Step a)

[0121] In a preferred embodiment, the protein (2) is an analyte binding protein, such as an antibody or fragment thereof.

[0122] In another preferred embodiment, the protein (2) is an analyte binding antibody or analyte binding fragment thereof.

[0123] In yet a preferred embodiment, the protein (2) is the (endogenous) target for a small molecule and / or has affinity for a small molecule. Phrased in another way, in an embodiment, the protein (2) has affinity for a small molecule and is not an antibody or fragment thereof, preferably the protein being the target for a small molecule in vivo.

[0124] In a related embodiment, the (endogenous) protein / target or derivative or fragment thereof is selected from the group consisting of enzymes, such as serine proteases such as Factor II and Factor X, or derivatives thereof, such as modified recombinant factor Xa protein Andexanet Alfa, Receptors, Isomerases, Ion Channels, Hormonal Proteins, Transport Proteins and Immunoglobulins.

[0125] In a preferred embodiment, the protein or derivative or fragment thereof exhibits affinity towards small molecule drugs, such as being proteins in the coagulation pathway such as Factor II (showing affinity towards Dabigatran), factor X (showing affinity towards factor X inhibitors such as Edoxaban, Apixaban and Rivaroxaban), Factor XI or modified Factor X proteins such as Andexanet Alfa (showing affinity towards factor X inhibitors such as Edoxaban, Apixaban and Rivaroxaban), or proteins developed by immune systems to specifically show affinity towards antigens such as IgG's and fragments thereof.

[0126] In another preferred embodiment, the protein or derivative or fragment thereof exhibits affinity towards small molecules, such as being antibodies and fragments thereof or being the factor X derivative Andexanet Alfa.83692PC01

[0127] 13

[0128] Andexanet alfa is an antidote for the medicaments rivaroxaban and apixaban, when reversal of anticoagulation is needed due to uncontrolled bleeding.

[0129] In yet an embodiment, the antibody or fragment thereof is selected from the group consisting of monoclonal, polyclonal, monospecific polyclonal, recombinant, chimeric, single chain antibodies, such as a Fab fragment, a F(ab')2, a Fv, a Fd, a dAb, a scFv fragment or a single-domain antibody (sdAb) such as a nanobody, and affibody. In the example section (examples 2-8) different types of antibodies have been tested.

[0130] In yet another embodiment, the antibody or fragment thereof is selected from the group consisting of single chain antibodies, such as a Fab fragment, a F(ab')2, a Fv, a Fd, a dAb, a scFv fragment or a single-domain antibody (sdAb) such as a nanobody, and affibody. As shown in e.g. example 2, conjugation to a Fab fragment produces exclusively a 1:1 ratio between the Fab fragment and the oligonucleotide (DAR=1).

[0131] Example 9 shows that the process of the invention is also functional for different types of proteins as shown by conjugation to e.g. Lysozyme, Factor Xa and Transferrin, generating DAR=1 conjugates.

[0132] Different types of (analyte binding) proteins (such as an antibody or fragment thereof) may be used in the process according to the invention. Thus, in an embodiment, the (analyte binding) protein is specific for or has affinity for a small molecule selected from the group consisting of:

[0133] I. Drugs such as selected from the group consisting of Atorvastatin, Levothyroxine, Lisinopril, Omeprazole, Metformin, Amlodipine, Simvastatin, Metoprolol, Losartan, Azithromycin, Zolpidem, Hydrochlorothiazide, Furosemide, Metoprolol, Pantoprazole, Gabapentin, Amoxicillin, Prednisone, Sertraline, Tamsulosin, Fluticasone, Pravastatin, Tramadol, Montelukast, Escitalopram, Carvedilol, Alprazolam, Warfarin, Meloxicam, Clopidogrel, Amoxicillin, Allopurinol, Bupropion, Lisinopril, Citalopram, Losartan, Atenolol, Cialis, Duloxetine, Fluoxetine, Fenofibrate, Crestor, Venlafaxine, Ventolin, Cyclobenzaprine, Trazodone, and Methylprednisolone;

[0134] II. (Illegal) food additives, such as selected from the group consisting of cinnamyl anthranilate, cobalt salts, coumarin, cyclamate, diethyl83692PC01

[0135] 14

[0136] pyrocarbonate (DEPC), dulcin (p-ethoxy-phenylurea), monochloroacetic acid, nordihydroguaiaretic acid (NDGA), oil of calamus, polyoxyethylene-8- stearate (Myrj 45), safrole, thiourea, and melamine;

[0137] III. Vitamins such as selected from the group consisting of all-trans-Retinol, Retinals, and alternative provitamin A-functioning Carotenoids including all- trans-beta-carotene, Thiamine, Riboflavin, Niacin, Niacinamide, Nicotinamide riboside, Pantothenic acid, Pyridoxine, Pyridoxamine, Pyridoxal, Biotin, Folates, Folic acid, Cyanocobalamin, Hydroxocobalamin, Methylcobalamin, Adenosylcobalamin, Ascorbic acid, Cholecalciferol (D3), Ergocalciferol (D2), Tocopherols, Tocotrienols, Phylloquinone, and Menaquinones;

[0138] IV. Exogenous Anabolic Androgenic Steroids (AAS), such as selected from the group consisting of 1-androstendiol, 1-androstendione, bolandiol, bolasterone, boldenone, boldione, calusterone, clostebol, danazol, dehydrochlormethyltestosterone, desoxymethyltestosterone, drosta noIone, ethylestrenol, fluoxymesterone, formebolone, furazabol, gestrinone, 4- hydroxytestosterone, mestanolone, mesterolone, metenolone, methandienone, methandriol, methasterone, methyldienolone, methyl-1- testosterone, methylnortestosterone, methyltrienolone, methyltestosterone, mibolerone, nandrolone, 19-norandrostenedione, norboletone, norclostebol, norethandrolone, oxabolone, oxandrolone, oxymesterone, oxymethoIone, prostanozol, quinbolone, stanozolol, stenbolone, 1-testosterone, tetra hydrogestri none and trenbolone.

[0139] V. Endogenous Anabolic Androgenic Steroids (AAS), such as selected from the group consisting of androstenediol, androstenedione, dihydrotestosterone, prasterone and testosterone;

[0140] VI. Other Anabolic Agents, such as selected from the group consisting of clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol and zilpaterol;

[0141] VII. Short-acting [32 agonists (SABAs), such as selected from the group consisting of bitolterol— Tornalate, fenoterol— Berotec, isoprenaline (INN) or isoproterenol (USAN)— Isuprel, levosalbutamol (INN) or levalbuterol (USAN)— Xopenex, orciprenaline (INN) or metaproterenol (USAN)— Alupent, pirbuterol— Maxair, procaterol, ritodrine— Yutopar, salbutamol (INN) or83692PC01

[0142] 15

[0143] albuterol (USAN)— Ventolin, terbutaline— Bricanyl and albuterol— Ventolin / Proventil;

[0144] VIII. Aromatase inhibitors such as including, but not limited to aminoglutethimide, anastrozole, exemestane, formestane, letrozole and testolactone;

[0145] IX. Selective estrogen receptor modulators (SERMs) including, but not limited to raloxifene, tamoxifen and toremifene;

[0146] X. Other anti-estrogenic substances, including but not limited to clomiphene, cyclofenil and fulvestrant; Diuretics, such as selected from the group consisting of acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides, triamterene, epitestosterone and probenecid; XI. Stimulants, such as selected from the group consisting of adrafinil, adrenaline, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, benzylpiperazine, bromantan, cathine, clobenzorex, cocaine, cropropamide, crotetamide, cyclazodone, dimethylamphetamine, ephedrine, etamivan, etilamphetamine, etilefrine, famprofazone, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, heptaminol, isometheptene, levmethamfetamine, meclofenoxate, mefenorex, mephentermine, mesocarb, methamphetamine (D-), methylenedioxyamphetamine, methylenedioxymethamphetamine, methylamphetamine, methylephedrine, methylphenidate, modafinil, nikethamide, norfenefrine, norfenfluramine, octopamine, ortetamine, oxilofrine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine, phenpromethamine, phentermine, 4- phenylpiracetam (carphedon), prolintane, propylhexedrine, selegiline, sibutramine, strychnine and tuaminoheptane;

[0147] XII. Antibiotics such as selected from the group consisting of Vancomycin, Teicoplanin, Linezolid, Daptomycin, Trimethoprim / sulfamethoxazole, Doxycycline, Ceftobiprole, Ceftaroline, Clindamycin, Dalbavancin, Fusidic acid, Mupirocin (topical), Omadacycline, Oritavancin, Tedizolid, Telavancin, Tigecycline, Pseudomonas aeruginosa, Carbapenems, Ceftazidime, Cefepime, Ceftobiprole, Ceftolozane, Fluoroquinolones, Piperacillin, Ticarcillin, Streptogramins, Tigecycline, Daptomycin, Amikacin, Gentamicin, Kanamycin, Neomycin, Netilmicin, Tobramycin, Paromomycin,83692PC01

[0148] 16

[0149] Streptomycin, Spectinomycin, Ansamycins, Geldanamycin, Herbimycin, Rifaximin, Carbacephem, Loracarbef, Carbapenems, Ertapenem, Doripenem, Imipenem, Meropenem, Cefadroxil, Cefazolin, Cephradine, Cephapirin, Cephalothin, Cefalexin, Cefaclor, Cefoxitin, Cefotetan, Cefamandole, Cefmetazole, Cefonicid, Loracarbef, Cefprozil, Cefuroxime, Cephalosporins, Cefixime, Cefdinir, Cefditoren, Cefoperazone, Cefoperazone, Cefotaxime, Cefpodoxime, Ceftazidime, Ceftibuten, Ceftizoxime, Moxalactam, Ceftriaxone, Cephalosporins, Cefepime, Cephalosporins, Ceftaroline fosamil, Ceftobiprole, Glycopeptides, Teicoplanin, Vancomycin, Telavancin, Dalbavancin, Oritavancin, Lincosamides, Clindamycin, Lincomycin, Lipopeptide, Daptomycin, Macrolides(Bs), Azithromycin, Clarithromycin, Erythromycin, Roxithromycin, Telithromycin, Spiramycin, Fidaxomicin, Monobactams, Aztreonam, Nitrofurans, Furazolidone, Nitrofurantoin(Bs), Oxazolidinones(Bs), Posizolid, Radezolid, Torezolid, Amoxicillin, Ampicillin, Azlocillin, Dicloxacillin, Flucioxacillin, Mezlocillin, Methicillin, Nafcillin, Oxacillin, Penicillin G, Penicillin V, Piperacillin, Penicillin G, Temocillin, Ticarcillin, Sulfacetamide, Sulfadiazine, Silver sulfadiazine, Sulfadimethoxine, Sulfamethizole, Sulfamethoxazole, Sulfanilimide (archaic), Sulfasalazine, Sulfisoxazole, Trimethoprim-Sulfamethoxazole, Sulfonamidochrysoidine (archaic), Tetracyclines, Demeclocycline, Doxycycline, Metacycline, Minocycline, Oxytetracycline, Tetracycline, Drugs against mycobacteria, Clofazimine, Dapsone, Capreomycin, Cycloserine, Ethambutol(Bs), Ethionamide, Isoniazid, Pyrazinamide, Rifampicin, Rifabutin, Rifapentine, Streptomycin; and

[0150] XIII. Compounds selected from the group consisting of Arsphenamine, Chloramphenicol, Fosfomycin, Fusidic acid, Metronidazole, Mupirocin, Platensimycin, Quinupristin / Dalfopristin, Thiamphenicol, Tigecycline, Tinidazole and Trimethoprim.

[0151] In a preferred embodiment, the antibody or fragment thereof is specific for or has affinity for a small molecule, such as a small molecule anticoagulant, such as selected from the group consisting of Rivaroxaban, Apixaban, Edoxaban and Dabigatran.83692PC01

[0152] 17

[0153] In yet a preferred embodiment, the antibody or fragment thereof is specific for or has affinity for a small molecule selected from the group consisting of Rivaroxaban, Apixaban, and Dabigatran or anticoagulants such as Warfarin, Edoxaban, Rivaroxaban and Betrixaban, and immunosuppressants such as Methotrexate, Cyclosporine, Tacrolimus, Sirolimus, and Everolimus, and illegal drugs such as Cannaboids, Cocaine, Opiates (Heroin), Methamphetamine, Amphetamine, and Phencyclidine.

[0154] In an embodiment, the small molecule has a size below or equal to 900 Daltons, such as in the range 100-900, 200-900, 300-900, 400-900 or 430-900 Daltons. In an embodiment, the protein (2) is not a metal-binding protein.

[0155] In another embodiment, the protein (2) is an antibody or fragment thereof.

[0156] Step b)

[0157] Different types of polymers can be used in the process according to the invention. A polyelectrolyte is a type of polymer that contains ionizable groups, which can dissociate in aqueous solutions to form charged particles, or ions. These charged groups can be either positively charged (cationic) or negatively charged (anionic). In an embodiment, the polyelectrolytes according to the invention are selected from the group consisting of:

[0158] Oligonucleotides such as DNA, RNA, XNA, LNA and other synthetic oligonucleotides;

[0159] Peptides such as poly-lysines, poly-glutamic acids or any combination of side chains in the peptide that results in an overall charged compound. - Synthetic polymers such as polyacrylic acid (PAA), Poly(sodium styrene sulfonate) (PSS), Polyvinyl sulfate (PVS) or similar.

[0160] In another embodiment, the polymer is a non-polyelectrolyte, such as the polymers polyethylene glycol (PEG), polyvinyl alcohol (PVA), and polyvinyl pyrrolidone (PVP), polysaccharides, neutral or near neutral peptides sequences or oligoes with backbone modifications rendering them neutral or near neutral in charge.

[0161] The polymer is preferably a polyelectrolyte, such as oligonucleotides, most preferably being DNA. In the example section DNA polymers have been tested as an example of a polymer, more specifically a polyelectrolyte.83692PC01

[0162] 18

[0163] The oligonucleotide used in the process, according to the invention may comprise modified nucleotides. Thus, in an embodiment, the oligonucleotide comprises one or more modified nucleotides, such as selected from the group consisting of PNA, LNA, xylo-LNA-, phosphorothioate-, 2'-methoxy-, 2'-methoxyethoxy-, morpholino-and phosphoramidate- containing nucleotides.

[0164] In another embodiment, the oligonucleotide (3) is a DNA or RNA oligonucleotide, preferably a DNA oligonucleotide. In the example section, DNA oligonucleotides are tested.

[0165] In yet an embodiment, the oligonucleotide (3) comprises a nucleotide comprising a modified moiety (5), such as Cy3. In the example section, Cy3 is tested and shown to have a positive effect on certain conjugation reactions when present on the oligonucleotide (see example 3), yet a negative effect when present in free form (see example 5).

[0166] In yet an embodiment, the modified moiety (5) is suitable as part of a fluorescent or optical pair, such as being Cy3.

[0167] In yet another embodiment, the protein is an antibody or fragment thereof having affinity for Dabigatran or Apixaban, and the modified moiety (5) is Cy3.

[0168] In an embodiment, the modified moiety (5) is positioned away from the outermost 2 nucleotides from the 5'-end and the 3'-end in the oligonucleotide. Thus, the modified moiety (5) may be positioned internally in the oligonucleotide.

[0169] In yet an embodiment, the oligonucleotide (3) has a length in the range 5-100 nucleotides, such as 10-50 nucleotides, such as 15-40, such as 15-30, such as 15-25 nucleotides. In examples 1-8, the oligonucleotide has a length of 22 nucleotides.

[0170] In an embodiment, the aldehyde modification (4) is at the 5'-end or 3'-end of the oligonucleotide, preferably at the 3'-end.

[0171] In yet an embodiment, the aldehyde modification is selected from the group consisting of formyl benzene and derivatives thereof, salicyl aldehyde and derivatives thereof, amides of glyoxal acid, proaldehydes that can be converted into aldehydes through the use of a chemical reagent such as periodate, amides83692PC01

[0172] 19

[0173] from tartrates as well as the amino acids serine, threonine, glycine, cysteine, 3'-RNA base, preferably the aldehyde being a 4-formylbenzoate moiety.

[0174] In a preferred embodiment, the aldehyde modification is a 4-formylbenzoate moiety. Such aldehyde has been tested in the example section.

[0175] In an embodiment, the 3' aldehyde modification (4) comprises a benzene ring.

[0176] In another embodiment, the 3' aldehyde modification (4) is selected from the group consisting of benzaldehyde, N-4-Formylbenzoate

[0177]

[0178] In a further embodiment, the oligonucleotide and the aldehyde moiety are coupled via a linker.

[0179] In an embodiment, the linker is selected from the group consisting of an amid linker, an ester linker, a thioether linker, a disulphide linker, a 1,2,3-triazole linker, a thiourea linker, an isourea linker, a 4-Mercaptobutyramidine linker, an isoxazole linker and a carbamate linker.

[0180] Step c)

[0181] Different types of reducing agents may be used in the process according to the invention. Thus, in an embodiment, the reducing agent is selected from the group consisting of 2-Methylpyridine borane complex, sodium cyanoborohydride (NaCNBHs), NaBH4, NaBH(OAc)3, sodium borohydride, sodium triacetoxyborohydride and decaborane, preferably being sodium cyanoborohydride (NaCNBHs). H2 and a reduction catalyst such as Palladium on Carbon (Pd / C), Platinum Oxide (PtO), Raney Nickel and NaBH(OAc)3, preferably being sodium cyanoborohydride (NaCNBHs).83692PC01

[0182] 20

[0183] In a preferred embodiment of the invention, the reducing agent is a water-soluble reducing agent, such as NaCNBHs, 2-Methylpyridine borane complex or combinations or derivatives thereof, such as Pyridine borane, 3-Methylpyridine borane, 4-Methylpyridine borane, 2-Ethylpyridine borane, 2-n-Propylpyridine borane, 3-Ethylpyridine borane, 4-Ethylpyridine borane, 2,3-Lutidine borane, 2,6-Lutidine borane, 2,4,6-Collidine borane, 5-Ethyl-2-methylpyridine borane.

[0184] As shown in example 10, both NaCNBHs and 2-Methylpyridine borane complex provided satisfactory results, however 2-Methylpyridine borane complex may be preferred due to safety reasons.

[0185] In an embodiment, in step c), the mixture also comprises a buffer, such as a selected from the group consisting of HEPES, PBS, MES, Bis-Tris, ADA, ACES, PIPES, MOPSO, Bis-Tris Propane, BES, MOPS, TES, HEPES, DIPSO, MOBS, TAPSO, Tris or Trizma®, HEPPSO, POPSO, TEA, EPPS, Tricine, Gly-Gly, Bicine, HEPBS, TAPS, AMPD, TABS, AMPSO, CHES, CAPSO, AMP, CAPS, and CABS.

[0186] In an embodiment, in step c), the molar ratio between protein and oligonucleotide is in the range 10:1 to 1:10, such as 1: 1 to 1:10, preferably such as 1: 1 to 1:5, more preferably such as 1: 1 to 1:3 such as 1: 1 to 1:2 such as around 1:1.

[0187] In a related embodiment, in step c), the reducing agent is in a molar surplus compared to the protein and / or oligonucleotide.

[0188] In a preferred embodiment, step c) and / or step d) are performed in the absence of the target for the (analyte binding) protein (2), such as an anticoagulant.

[0189] As explained in the example section, it has been identified that the conjugation reaction can be improved when low salt is used.

[0190] In a related embodiment, in step c) and / or step d), the mixture comprises salt in the range

[0191] Mg in the range 0-40 mM; or

[0192] Na in the range 0-400 mM; or

[0193] K in the range 0-400 mM.83692PC01

[0194] 21

[0195] In an embodiment, step c) and / or d) is performed in a total salt concentration equal to or below 250 mM, preferably equal to or below 150 mM, more preferably equal to or below 100 mM, and even more preferably equal to or below 50 mM, such as equal to or below 10 mM or being free or substantially free of salt.

[0196] In a related embodiment, step c) and / or d) is performed in a total salt concentration in the range 5-400 mM, such as 5-250 mM, such as in the range 5-150 mM, more preferably in the range 5-100 mM, and even more preferably in the range 5-50 mM.

[0197] In yet an embodiment, the salt is selected from the group consisting of NaCI, MgC , KCI, CaCl2, NaOAc, Na2SO4, (NH4)2SO4, K2HPO4, and KH2PO4.

[0198] In a further embodiment, in step c) and / or step d),

[0199] - the monovalent cation concentration is below 400 mM; and / or

[0200] - the divalent cation concentration is below 20 mM; and / or

[0201] - the trivalent cation concentration below 2 mM.

[0202] In a related embodiment, in step c) and / or step d), the mixture comprises salt in the range:

[0203] • monovalent cations below 400 mM and being free or substantially free of divalent and trivalent cations; or

[0204] • divalent cations below 20 mM and being free or substantially free of monovalent and trivalent cations; or

[0205] • trivalent cations below 2 mM and being free or substantially free of monovalent and divalent cations.

[0206] In yet an embodiment, in step c) and / or step d), the mixture being free or substantially free of cations with a valence higher than the trivalence.

[0207] In another embodiment,

[0208] under point a) the concentration of monovalent cations is below 250 mM, preferably equal to or below 150 mM, more preferably equal to or below 100 mM, and even more preferably equal to or below 50 mM, such as equal83692PC01

[0209] 22

[0210] to or below 10 mM or being free or substantially free of monovalent cations; or

[0211] under point b) the concentration of divalent cations is below 15 mM, preferably equal to or below 10 mM, more preferably equal to or below 5 mM, and even more preferably equal to or below 1 mM, or being free or substantially free of divalent cations; or

[0212] under point c) the concentration of trivalent cations is below 1 mM, preferably equal to or below 0.5 mM, more preferably equal to or below 0.1 mM, being free or substantially free of trivalent cations.

[0213] In yet a further embodiment,

[0214] monovalent cations are selected from the group consisting of Sodium (Na+) Potassium (K+), and Ammonium (NH4+);

[0215] - divalent cations are selected from the group consisting of Calcium (Ca2+), Magnesium (Mg2+), and Zinc (Zn2+); and

[0216] trivalent cations are selected from the group consisting of Ferric (Fe3+) and Aluminum (Al3+).

[0217] In a preferred embodiment, the salt is a monovalent cation selected from Sodium (Na+) and Magnesium (Mg2+).

[0218] Step d)

[0219] In an embodiment, in step d), the reaction is for 5 minutes to 72 hours, such as 5 minutes to 24 hours, such as 1-16 hours, such as 1-12 hours, such as 1-8, such as 4-8 hours, preferably at a temperature in the range 3-45°C, such as 3-37°C, such as 10-30°C, such as 15-30°C, such as 20-25°C, such as around room temperature.

[0220] In an embodiment, step c) and / or d) is performed in the absence of an oligonucleotide able to hybridise to the polymer (3) from step b), such as the polymer being an oligonucleotide.

[0221] In yet an embodiment, step c) and / or d) is performed in the absence of a second oligonucleotide able to hybridise to the oligonucleotide (3) from step b).83692PC01

[0222] 23

[0223] In an embodiment, step c) and / or d) are performed in a total salt concentration equal to or below 250 mM, preferably equal to or below 170 mM, more preferably equal to or below 100 mM, and even more preferably equal to or below 50 mM, such as equal to or below 10 mM or being free or substantially free of salt.

[0224] In a related embodiment, step c) and / or d) is performed in a total salt concentration in the range 5-250 mM, such as in the range 5-150 mM, more preferably in the range 5-100 mM, and even more preferably in the range 5-50 mM.

[0225] In yet a related embodiment, the salt is selected from the group consisting of NaCI, MgC , KCI, CaCI2, NaOAc, Na2SO4, (NH4)2SO4, K2HPO4, and KH2PO4.

[0226] As shown in examples 3, 6, and 7, the pH also has an influence on the conjugation efficiency, albeit being robust over wide range of pH, only decreasing the yield at very high pH. Thus, in an embodiment, in step c) and / or step d) the pH is in the range 4-9.5, such as 5-8, preferably in the range 7-7.5. In an embodiment, in step c) and / or step d) the pH is in the range 4-7.3, such as 4-7, 4-6.5, 4-6, 5-7, or 5-6. The pH around 7 is usually the least stressful for the protein and thus preferred. Albeit yield may improve at lower pH as outlined in the example section.

[0227] Step e)

[0228] As outlined in the example section, it has been found that the process of the invention is well-suited to produce conjugates having one or two DNA oligonucleotides (3) per protein and thus not being heavily conjugated. Thus, in an embodiment, in step e), the provided protein-DNA conjugates (1) have at least 30% conjugates having one or two DNA oligonucleotides (3) per protein, preferably at least 40%, more preferably at least 50%. (DAR=1 and DAR=2), based on a calculation of HPLC chromatograms, in which the integrals of the corresponding conjugate (DAR=1 and DAR=2) equal to at least 30, 40 or 50%.

[0229] The process can also be directed to have a high yield of DAR=1. Thus, in an embodiment, in step e), the provided protein-DNA conjugates (1) have at least 10% conjugates having at most one DNA oligonucleotide (3) per protein.83692PC01

[0230] 24

[0231] (DAR=1).

[0232] The process can also be modulated to yield of the different protein-DNA conjugates being DAR=1 and DAR=2, by changing the ratio between aldehyde-modified DNA (4) and the protein (2) during the reaction. Changing the amount of aldehyde-modified DNA changes the ratio of DAR=1 / DAR=2 from 6.25 at 2 equiv. aldehyde-modified DNA (4) to 2.3 at 5 equiv. aldehyde-modified DNA (4).

[0233] As shown in example 2, Fab fragments tend to have a higher ratio of conjugates conjugated to only one oligonucleotide, likely due to the smaller size. Thus, in a preferred embodiment, the the protein is a Fab fragment; and in step e) the provided protein-DNA conjugates (1) have at least 70% conjugates having at the most one DNA oligonucleotide (3) per protein, preferably at least 80% conjugates and more preferably at least 90% conjugates and even more preferably at least 95% of the conjugates have at the most one DNA oligonucleotide (3) per protein.

[0234] In an embodiment, the composition provided in step e), comprises less than 60% unconjugated proteins (2).

[0235] In an embodiment, the oligonucleotide is coupled to the protein via an amine, such as a lysine in the protein or the N-terminal of the protein.

[0236] Further steps

[0237] The conjugates may also be subsequently purified, e.g. based on the number of conjugates. Thus, in an embodiment, the process further comprises the step: f) purifying the protein-oligonucleotide conjugate, such as by HPLC and / or anion exchange chromatography and / or size exclusion, preferably the protein-oligonucleotide conjugates comprising one or two oligonucleotides per protein are purified.

[0238] The conjugates may have different uses. Thus, in an embodiment, the process is for providing protein-oligonucleotide conjugates (1) to be used in competitive immunoassays, such as for detection of small molecule drugs in solution by FRET, such as based on an antibody-oligonucleotide-donor dye and a competitive binder-oligonucleotide-acceptor dye.83692PC01

[0239] 25

[0240] In a related embodiment, the process further comprises using the provided protein-oligonucleotide conjugates (1) in a competitive immunoassay, such as for the detection of small molecule drugs in solution by FRET, such as based on an antibody-oligonucleotide-donor dye and a competitive binder-oligonucleotide-acceptor dye.

[0241] Products obtained by process

[0242] An aspect of the invention relates to a protein-oligonucleotide conjugate (1) obtained by or obtainable by the process according to the invention.

[0243] Uses

[0244] Another aspect of the invention relates to the use of a protein-oligonucleotide conjugate (1) obtained by or obtainable by a process according to the invention in a competitive immunoassay, such as for detection of small molecule drugs in solution by FRET, such as based on an antibody-oligonucleotide-donor dye and a competitive binder-oligonucleotide-acceptor dye.

[0245] Items of the invention

[0246] 1. A process for preparing a protein-polymer conjugate (1); the process comprising the steps of:

[0247] a) providing a protein (2), preferably an antibody or fragment thereof; b) providing a polymer (3), preferably a polyelectrolyte, more preferably an oligonucleotide, and even more preferably a DNA oligonucleotide, the polymer comprising

[0248] i. an aldehyde moiety (4), preferably being a 4-formylbenzoate moiety; and

[0249] c) mixing the protein (2) from step a) with the polymer (3) from step b) in the presence of a reducing agent, preferably NaCNBHs, and

[0250] wherein the total salt concentration in the mixture is below 400 mM; d) incubating the mixture from step c), such as for at least 5 minutes at a temperature in the range of 3-45 °C; and

[0251] e) providing a composition comprising covalently linked protein-polymer conjugates (1).83692PC01

[0252] 26

[0253] 2. A process for preparing a protein-oligonucleotide conjugate (1); the process comprising the steps of:

[0254] a) providing a protein (2), preferably an antibody or fragment thereof; b) providing an oligonucleotide (3), preferably a DNA oligonucleotide, the oligonucleotide comprising

[0255] i. an aldehyde moiety (4), preferably being a 4-formylbenzoate moiety, preferably the aldehyde moiety being coupled via the 3'-end of the oligonucleotide; and

[0256] c) mixing the protein (2) from step a) with the oligonucleotide (3) from step b) in the presence of a reducing agent, preferably NaCNBHs, and wherein the total salt concentration in the mixture is below 400 mM; d) incubating the mixture from step c), such as for at least 5 minutes at a temperature in the range of 3-45°C; and

[0257] e) providing a composition comprising covalently linked protein- oligonucleotide conjugates (1).

[0258] 3. The process according to item 1 or 2, wherein the protein (2) is an analytebinding protein, such as an antibody or fragment thereof; and / or the protein (2) is an analyte-binding antibody or analyte-binding fragment thereof.

[0259] 4. The process according to item 1 or 2, wherein the protein (2) is the endogenous target for a small molecule and / or has affinity for a small molecule.

[0260] 5. The process according to item 2 or 3, wherein the antibody or fragment thereof is selected from the group consisting of monoclonal, polyclonal, monospecific polyclonal, recombinant, chimeric, single chain antibodies, such as a Fab fragment, a F(ab')2, a Fv, a Fd, a dAb, a scFv fragment or a single-domain antibody (sdAb) such as a nanobody, and affibody.

[0261] 6. The process according to item 5, wherein the antibody or fragment thereof is selected from the group consisting of single chain antibodies, such as a Fab fragment, a F(ab')2, a Fv, a Fd, a dAb, a scFv fragment or a single-domain antibody (sdAb) such as a Nanobody, and affibody.83692PC01

[0262] 27

[0263] 7. The process according to any of the preceding items, wherein protein is specific for or has affinity for a small molecule selected from the group consisting of:

[0264] I. Drugs such as selected from the group consisting of Atorvastatin, Levothyroxine, Lisinopril, Omeprazole, Metformin, Amlodipine, Simvastatin, Metoprolol, Losartan, Azithromycin, Zolpidem, Hydrochlorothiazide, Furosemide, Metoprolol, Pantoprazole, Gabapentin, Amoxicillin, Prednisone, Sertraline, Tamsulosin, Fluticasone, Pravastatin, Tramadol, Montelukast, Escitalopram, Carvedilol, Alprazolam, Warfarin, Meloxicam, Clopidogrel, Amoxicillin, Allopurinol, Bupropion, Lisinopril, Citalopram, Losartan, Atenolol, Cialis, Duloxetine, Fluoxetine, Fenofibrate, Crestor, Venlafaxine, Ventolin, Cyclobenzaprine, Trazodone, and Methylprednisolone;

[0265] II. (Illegal) food additives, such as selected from the group consisting of cinnamyl anthranilate, cobalt salts, coumarin, cyclamate, diethyl pyrocarbonate (DEPC), dulcin (p-ethoxy-phenylurea), monochloroacetic acid, nordihydroguaiaretic acid (NDGA), oil of calamus, polyoxyethylene-8- stearate (Myrj 45), safrole, thiourea, and melamine;

[0266] III. Vitamins such as selected from the group consisting of all-trans-Retinol, Retinals, and alternative provitamin A-functioning Carotenoids including all- trans-beta-carotene, Thiamine, Riboflavin, Niacin, Niacinamide, Nicotinamide riboside, Pantothenic acid, Pyridoxine, Pyridoxamine, Pyridoxal, Biotin, Folates, Folic acid, Cyanocobalamin, Hydroxocobalamin, Methylcobalamin, Adenosylcobalamin, Ascorbic acid, Cholecalciferol (D3), Ergocalciferol (D2), Tocopherols, Tocotrienols, Phylloquinone, and Menaquinones;

[0267] IV. Exogenous Anabolic Androgenic Steroids (AAS), such as selected from the group consisting of 1-androstendiol, 1-androstendione, bolandiol, bolasterone, boldenone, boldione, calusterone, clostebol, danazol, dehydrochlormethyltestosterone, desoxymethyltestosterone, drostanolone, ethylestrenol, fluoxymesterone, formebolone, furazabol, gestrinone, 4- hydroxytestosterone, mestanolone, mesterolone, metenolone, methandienone, methandriol, methasterone, methyldienolone, methyl-1- testosterone, methylnortestosterone, methyltrienolone, methyltestosterone, mibolerone, nandrolone, 19-norandrostenedione, norboletone, norclostebol, norethandrolone, oxabolone, oxandrolone,83692PC01

[0268] 28

[0269] oxymesterone, oxymethoIone, prostanozol, quinbolone, stanozolol, stenbolone, 1-testosterone, tetra hydrogestri none and trenbolone.

[0270] V. Endogenous Anabolic Androgenic Steroids (AAS), such as selected from the group consisting of androstenediol, androstenedione, dihydrotestosterone, prasterone and testosterone;

[0271] VI. Other Anabolic Agents, such as selected from the group consisting of clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol and zilpaterol;

[0272] VII. Short-acting [32 agonists (SABAs), such as selected from the group consisting of bitolterol— Tornalate, fenoterol— Berotec, isoprenaline (INN) or isoproterenol (USAN)— Isuprel, levosalbutamol (INN) or levalbuterol (USAN)— Xopenex, orciprenaline (INN) or metaproterenol (USAN)— Alupent, pirbuterol— Maxair, procaterol, ritodrine— Yutopar, salbutamol (INN) or albuterol (USAN)— Ventolin, terbutaline— Bricanyl and albuterol— Ventolin / Proventil;

[0273] VIII. Aromatase inhibitors such as including, but not limited to aminoglutethimide, anastrozole, exemestane, formestane, letrozole and testolactone;

[0274] IX. Selective estrogen receptor modulators (SERMs) including, but not limited to raloxifene, tamoxifen and toremifene;

[0275] X. Other anti-estrogenic substances, including but not limited to clomiphene, cyclofenil and fulvestrant; Diuretics, such as selected from the group consisting of acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides, triamterene, epitestosterone and probenecid; XI. Stimulants, such as selected from the group consisting of adrafinil, adrenaline, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, benzylpiperazine, bromantan, cathine, clobenzorex, cocaine, cropropamide, crotetamide, cyclazodone, dimethylamphetamine, ephedrine, etamivan, etilamphetamine, etilefrine, famprofazone, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenproporex, furfenorex, heptaminol, isometheptene, levmethamfetamine, meclofenoxate, mefenorex, mephentermine, mesocarb, methamphetamine (D-), methylenedioxyamphetamine, methylenedioxymethamphetamine, methylamphetamine, methylephedrine, methylphenidate, modafinil,83692PC01

[0276] 29

[0277] nikethamide, norfenefrine, norfenfluramine, octopamine, ortetamine, oxilofrine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine, phenpromethamine, phentermine, 4- phenylpiracetam (carphedon), prolintane, propylhexedrine, selegiline, sibutramine, strychnine and tuaminoheptane;

[0278] XII. Antibiotics such as selected from the group consisting of Vancomycin, Teicoplanin, Linezolid, Daptomycin, Trimethoprim / sulfamethoxazole, Doxycycline, Ceftobiprole, Ceftaroline, Clindamycin, Dalbavancin, Fusidic acid, Mupirocin (topical), Omadacycline, Oritavancin, Tedizolid, Telavancin, Tigecycline, Pseudomonas aeruginosa, Carbapenems, Ceftazidime, Cefepime, Ceftobiprole, Ceftolozane, Fluoroquinolones, Piperacillin, Ticarcillin, Streptogramins, Tigecycline, Daptomycin, Amikacin, Gentamicin, Kanamycin, Neomycin, Netilmicin, Tobramycin, Paromomycin, Streptomycin, Spectinomycin, Ansamycins, Geldanamycin, Herbimycin, Rifaximin, Carbacephem, Loracarbef, Carbapenems, Ertapenem, Doripenem, Imipenem, Meropenem, Cefadroxil, Cefazolin, Cephradine, Cephapirin, Cephalothin, Cefalexin, Cefaclor, Cefoxitin, Cefotetan, Cefamandole, Cefmetazole, Cefonicid, Loracarbef, Cefprozil, Cefuroxime, Cephalosporins, Cefixime, Cefdinir, Cefditoren, Cefoperazone, Cefoperazone, Cefotaxime, Cefpodoxime, Ceftazidime, Ceftibuten, Ceftizoxime, Moxalactam, Ceftriaxone, Cephalosporins, Cefepime, Cephalosporins, Ceftaroline fosamil, Ceftobiprole, Glycopeptides, Teicoplanin, Vancomycin, Telavancin, Dalbavancin, Oritavancin, Lincosamides, Clindamycin, Lincomycin, Lipopeptide, Daptomycin, Macrolides(Bs), Azithromycin, Clarithromycin, Erythromycin, Roxithromycin, Telithromycin, Spiramycin, Fidaxomicin, Monobactams, Aztreonam, Nitrofurans, Furazolidone, Nitrofurantoin(Bs), Oxazolidinones(Bs), Posizolid, Radezolid, Torezolid, Amoxicillin, Ampicillin, Azlocillin, Dicloxacillin, Flucioxacillin, Mezlocillin, Methicillin, Nafcillin, Oxacillin, Penicillin G, Penicillin V, Piperacillin, Penicillin G, Temocillin, Ticarcillin, Sulfacetamide, Sulfadiazine, Silver sulfadiazine, Sulfadimethoxine, Sulfamethizole, Sulfamethoxazole, Sulfanilimide (archaic), Sulfasalazine, Sulfisoxazole, Trimethoprim-Sulfamethoxazole, Sulfonamidochrysoidine (archaic), Tetracyclines, Demeclocycline, Doxycycline, Metacycline, Minocycline, Oxytetracycline, Tetracycline, Drugs83692PC01

[0279] 30

[0280] against mycobacteria, Clofazimine, Dapsone, Capreomycin, Cycloserine, Ethambutol(Bs), Ethionamide, Isoniazid, Pyrazinamide, Rifampicin, Rifabutin, Rifapentine, Streptomycin; and

[0281] XIII. Compounds selected from the group consisting of Arsphenamine, Chloramphenicol, Fosfomycin, Fusidic acid, Metronidazole, Mupirocin, Platensimycin, Quinupristin / Dalfopristin, Thiamphenicol, Tigecycline, Tinidazole and Trimethoprim.

[0282] 8. The process according to any of items 2-3 or 5-6, wherein the protein, such as an antibody or fragment thereof, is specific for or has affinity for a small molecule, such as a small molecule anticoagulant, such as selected from the group consisting of Rivaroxaban, Apixaban, Edoxaban and Dabigatran.

[0283] 9. The process according to any of items 2-3 or 5-7, wherein the protein, such as an antibody or fragment thereof, is specific for or has affinity for a small molecule selected from the group consisting of Rivaroxaban, Apixaban, and Dabigatran or anticoagulants such as Warfarin, Edoxaban, Rivaroxaban and Betrixaban, and immunosuppressants such as Methotrexate, Cyclosporine, Tacrolimus, Sirolimus, and Everolimus, and illegal drugs such as Cannaboids, Cocaine, Opiates (Heroin), Methamphetamine, Amphetamine, and Phencyclidine.

[0284] 10. The process according to any of the preceding items 4 or 8, wherein the small molecule has a size below or equal to 900 Daltons, such as in the range 100-900, 200-900, 300-900, 430-900 or 500-900 Daltons.

[0285] 11. The process according to item 1 or 4, wherein the (endogenous) protein or derivative or fragment thereof is selected from the group consisting of enzymes, such as serine proteases such as Factor II and Factor X, or derivatives thereof, such as modified recombinant factor Xa protein Andexanet Alfa, Receptors, Isomerases, Ion Channels, Hormonal Proteins, Transport Proteins and Immunoglobulins (defined previously), preferably the protein or derivative or fragment thereof exhibits affinity towards small molecule drugs, such as being proteins in the coagulation pathway such as Factor II (showing affinity towards Dabigatran), factor X (showing affinity towards factor X inhibitors such as Edoxaban, Apixaban and Rivaroxaban), Factor XI or modified Factor X proteins83692PC01

[0286] 31

[0287] such as Andexanet Alfa (showing affinity towards factor X inhibitors such as Edoxaban, Apixaban and Rivaroxaban), or proteins developed by immune systems to specifically show affinity towards antigens such as IgG's and fragments thereof, more preferably the protein exhibits affinity towards small molecules, such as being antibodies and fragments thereof or being the factor X derivative Andexanet Alfa.

[0288] 12. The process according to any of the preceding items, wherein the oligonucleotide comprises one or more modified nucleotides, such as selected from the group consisting of PNA, LNA, xylo-LNA-, phosphorothioate-, 2'-methoxy-, 2'-methoxyethoxy-, 2' fluoro-, morpholino- and phosphoramidate-containing nucleotides, preferably the oligonucleotide (3) is a DNA or RNA oligonucleotide, preferably a DNA oligonucleotide.

[0289] 13. The process according to any of the preceding items, wherein the oligonucleotide (3) comprises a nucleotide comprising a modified moiety (5), such as a Cy3 moiety.

[0290] 14. The process according to item 13, wherein the modified moiety (5) is suitable as part of a fluorescent or optical pair, such as being Cy3.

[0291] 15. The process according to item 13 or 14, wherein the protein is an antibody or fragment thereof having affinity for Dabigatran or Apixaban and the modified moiety (5) is Cy3.

[0292] 16. The process according to any of the preceding items 13-15, wherein the modified moiety (5) is positioned away from the outermost 2 nucleotides from the 5'-end and the 3'-end in the oligonucleotide, such as being internally positioned in the oligonucleotide.

[0293] 17. The process according to any of the preceding items, wherein the oligonucleotide (3) has a length in the range 5-100 nucleotides, such as 10-50 nucleotides, such as 15-40, such as 15-30, such as 15-25 nucleotides.83692PC01

[0294] 32

[0295] 18. The process according to any of the preceding items, wherein the aldehyde modification is selected from the group consisting formyl benzene and derivatives thereof, salicyl aldehyde and derivatives thereof, amides of glyoxal acid, proaldehydes that can be converted into aldehydes through the use of a chemical reagent such as periodate, amides from tartrates as well as the amino acids serine, threonine, glycine, cysteine, 3'-RNA base, succinimides, such as a succinimide comprising a benzaldehyde group, such as N-succinimidyl 4-formylbenzoate, preferably the aldehyde being a 4-formylbenzoate moiety.

[0296] 19. The process according to any of the preceding items, wherein the aldehyde modification is a 4-formylbenzoate moiety.

[0297] 20. The process according to any of the preceding items, wherein the 3' aldehyde modification (4) comprises a benzene ring.

[0298] 21. The process according to any of the preceding items, wherein the 3' aldehyde modification (4) is selected from the group consisting of benzaldehyde, N-4-formylbenzoate.

[0299]

[0300] 22. The process according to any of the preceding items, wherein the aldehyde modification (4) is at one of the ends of the polymer, preferably at the

[0301] 5'-end or the 3'-end of the oligonucleotide (when the polymer is an oligonucleotide), preferably at the 3'-end of the oligonucleotide.

[0302] 23. The process according to any of the preceding items, wherein the polymer (preferably an oligonucleotide) and the aldehyde moiety are coupled via a linker.

[0303] 24. The process according to item 23, wherein the linker is selected from the group consisting of an amide linker, an ester linker, a thioether linker, a83692PC01

[0304] 33

[0305] disulphide linker, a 1,2,3-triazole linker, a thiourea linker, an isourea linker, a 4-mercaptobutyramidine linker, an isoxazole linker and a carbamate linker.

[0306] 25. The process according to any of the preceding items, wherein the reducing agent is selected from the group consisting of sodium cyanoborohydride (NaCNBHs), sodium borohydride, sodium triacetoxyborohydride, and decaborane, preferably being sodium cyanoborohydride (NaCNBHs).

[0307] 26. The process according to any of the preceding items, wherein in step c), the mixture also comprises a buffer, such as a selected from the group consisting of HEPES, PBS, MES, Bis-Tris, ADA, ACES, PIPES, MOPSO, Bis-Tris Propane, BES, MOPS, TES, HEPES, DIPSO, MOBS, TAPSO, Tris or Trizma®, HEPPSO, POPSO, TEA, EPPS, Tricine, Gly-Gly, Bicine, HEPBS, TAPS, AMPD, TABS, AMPSO, CHES, CAPSO, AMP, CAPS, and CABS.

[0308] 27. The process according to any of the preceding items, wherein in step c), the molar ratio between protein and polymer (preferably an oligonucleotide) is in the range 10:1 to 1:10, such as 1:1 to 1:10, preferably such as 1:1 to 1:5: more preferably such as 1: 1 to 1:3 such as 1: 1 to 1:2 such as around 1:1.

[0309] 28. The process according to any of the preceding items, wherein in step c), the reducing agent is in a molar surplus compared to the protein and / or polymer (preferably oligonucleotide).

[0310] 29. The process according to any of the preceding items, wherein step c) and / or step d) are performed in the absence of a target for the protein (2), such as an anticoagulant.

[0311] 30. The process according to any of the preceding items wherein step c) and / or d) is performed in a total salt concentration equal to or below 250 mM, preferably equal to or below 150 mM, more preferably equal to or below 100 mM, and even more preferably equal to or below 50 mM, such as equal to or below 10 mM or being free or substantially free of salt.83692PC01

[0312] 34

[0313] 31. The process according to any of the preceding items 1-29, wherein step c) and / or d) is performed in a total salt concentration in the range 5-399 mM, such as 5-250 mM, such as in the range 5-150 mM, more preferably in the range 5-lOOmM, and even more preferably in the range 5-50 mM.

[0314] 32. The process according to any of the preceding items, wherein the salt is selected from the group consisting of NaCI, MgC , KCI, CaC , NaOAc, NazSC , (NH4)2SO4, K2HPO4, and KH2PO4.

[0315] 33. The process according to any of the preceding items, wherein in step c) and / or step d),

[0316] - the monovalent cation concentration is below 400 mM, and / or

[0317] - the divalent cation concentration is below 20 mM; and / or

[0318] - the trivalent cation concentration below 2 mM.

[0319] 34. The process according to any of the preceding items, wherein in step c) and / or step d), the mixture comprises salt in the range:

[0320] a) monovalent cations below 400 mM and being free or substantially free of divalent and trivalent cations; or

[0321] b) divalent cations below 20 mM and being free or substantially free of monovalent and trivalent cations; or

[0322] c) trivalent cations below 2 mM and being free or substantially free of monovalent and divalent cations.

[0323] 35. The process according to item 33, wherein

[0324] under point a) the concentration of monovalent cations is below 250 mM, preferably equal to or below 150 mM, more preferably equal to or below lOOmM, and even more preferably equal to or below 50 mM, such as equal to or below 10 mM or being free or substantially free of monovalent cations; or

[0325] under point b) the concentration of divalent cations is below 15 mM, preferably equal to or below 10 mM, more preferably equal to or below 583692PC01

[0326] 35

[0327] mM, and even more preferably equal to or below ImM, or being free or substantially free of divalent cations; or

[0328] under point c) the concentration of trivalent cations is below 1 mM, preferably equal to or below 0.5 mM, more preferably equal to or below 0.1 mM, being free or substantially free of trivalent cations.

[0329] 36. The process according to any of items 32-34, wherein

[0330] monovalent cations are selected from the group consisting of Sodium (Na+) Potassium (K+) and Ammonium (NH4+);

[0331] - divalent cations are selected from the group consisting of Calcium (Ca2+), Magnesium (Mg2+), and Zinc (Zn2+); and

[0332] trivalent cations are selected from the group consisting of Ferric (Fe3+) and Aluminum (Al3+).

[0333] 37. The process according to any of the preceding items, wherein in step d), the reaction is for 5 minutes to 72 hours, such 5 minutes to 24 hours, such as 1-16 hours, such as 1-12 hours, such as 1-8, such as 4-8 hours, preferably at a temperature in the range 3-45°C, such as 3- 37°C, such as 10-30°C, such as 15-30°C, such as 20-25°C, such as around room temperature.

[0334] 38. The process according to any of the preceding items, wherein step c) and / or d) is performed in the absence of a second oligonucleotide able to hybridise to the oligonucleotide (3) from step b), with the proviso that the polymer is an oligonucleotide.

[0335] 39. The process according to any of the preceding items, wherein in step c) and / or step d) the pH is in the range 4-8.5, such as 5-8, preferably in the range 6-7.3 or such as the pH is in the range 4-7.3, such as 4-7, 4-6.5, 4-6, 5-7, or 5-6.

[0336] 40. The process according to any of the preceding items, wherein in step e), the provided protein-DNA conjugates (1) have at least 30% conjugates having one or two DNA oligonucleotide (3) per protein, preferably at least 40%, more preferably at least 50% (DAR=1 and DAR=2);

[0337] or83692PC01

[0338] 36

[0339] the process according to any of the preceding items, wherein in step e), the provided protein-polymer conjugates (1) have at least 30% conjugates having one or two polymers (3) per protein, preferably at least 40%, more preferably at least 50%; (DAR=1 and DAR=2)

[0340] 41. The process according to any of the preceding items, wherein in step e), the provided protein-DNA conjugates (1) have at least 10% conjugates having at most one DNA oligonucleotide (3) per protein (DAR=1);

[0341] or

[0342] the process according to any of the preceding items, wherein in step e), the provided protein-polymer conjugates (1) have at least 10% conjugates having at most one polymer (3) per protein (DAR=1);

[0343] 42. The process according to any of the preceding items, wherein the composition provided in step e), comprises less than 60% unconjugated proteins (2).

[0344] 43. The process according to any of the preceding items, wherein the protein is a Fab fragment; and in step e) the provided protein-DNA conjugates (1) have at least 70% conjugates having at the most one DNA oligonucleotide (3) per protein, preferably at least 80% conjugates and more preferably at least 90% conjugates and even more preferably at least 95% of the conjugates have at the most one DNA oligonucleotide (3) per protein; or

[0345] the process according to any of the preceding items, wherein the protein is a Fab fragment; and in step e) the provided protein-polymer conjugates (1) have at least 70% conjugates having at the most one polymer (3) per protein, preferably at least 80% conjugates and more preferably at least 90% conjugates and even more preferably at least 95% of the conjugates have at the most one polymer (3) per protein.

[0346] 44. The process according to any of the preceding items, wherein the polymer is an oligonucleotide and the oligonucleotide is coupled to the protein via an amine, such as a lysine in the protein or the N-terminal end of the protein.

[0347] 45. The process according to any of the preceding items, wherein the process further comprises the step:83692PC01

[0348] 37

[0349] f) purifying the protein-polymer conjugate, preferably a protein- oligonucleotide conjugate, such as by HPLC and / or anion exchange chromatography and / or size exclusion, preferably the protein-polymer conjugates comprising one or two polymers per protein are purified.

[0350] 46. The process according to any of the preceding items, wherein the process is for providing protein-polymer conjugates (1) to be used in competitive immunoassays, such as for detection of small molecule drugs in solution by FRET, such as based on an antibody-polymer-donor dye and a competitive binder-polymer-acceptor dye; preferably the polymer is an oligonucleotide.

[0351] 47. The process according to any of the preceding items, further comprising using the provided protein-polymer conjugates (1) in a competitive immunoassay, such as for detection of small molecule drugs in solution by FRET, such as based on an antibody- polymer -donor dye and a competitive binder- polymer -acceptor dye; preferably the polymer is an oligonucleotide.

[0352] 48. A protein-polymer conjugate (1) obtained by or obtainable by the process according to any of the preceding items 1-44, preferably the polymer is an polyelectrolyte, more preferably and DNA oligonucloetide.

[0353] 49. Use of a protein-polymer conjugate (1) according to item 39 in a competitive immunoassay, such as for detection of small molecule drugs in solution by FRET, such as based on an antibody- polymer-donor dye and a competitive binder-polymer-acceptor dye; preferably the polymer is an polyelectrolyte, more preferably and DNA oligonucloetide.

[0354] It should be noted that embodiments and features described in the context of one of the aspects of the present invention also apply to the other aspects of the invention. For example, embodiments relating to protein-oligonucleotide conjugates are also applicable to embodiments relating to protein-polymer conjugates and vice versa.

[0355] All patent and non-patent references cited in the present application, are hereby incorporated by reference in their entirety.83692PC01

[0356] 38

[0357] The invention will now be described in further detail in the following non-limiting examples.

[0358] Examples

[0359] Example 1 - Materials and methods

[0360] For all the examples listed below the following setup was used:

[0361] Oligonucleotides were boug wht with commercially available modification from IDT and concentrations were determined on a Thermo Fisher Scientific ND-1000 NanoDrop spectrophotometer using c extinction coefficient supplied by IDT. All reagents were commercially available and bought from Sigma Aldrich unless stated otherwise. Dabigatran was purchased from Cayman Chemical Company.

[0362] J / J ° V

[0363] Table 2: Sequences, modifications and other compounds

[0364] Strand Name Sequence 5' 3'

[0365] SEQ ID NO: 1 ACATACAGCCTCGCATGAG-Internal Cy3-CCC-C6 aminomodification

[0366] SEQ ID NO: 2 ACATACAGCCTCGCATGAG-T-CCC-C6 amino-modification

[0367] Internal Cy3

[0368] modification

[0369] 3' C6 amino

[0370] modification

[0371] OH

[0372]

[0373] 83692PC01

[0374] 4-formylbenzoic 0,

[0375] 0

[0376] acid NHS (CAS /

[0377] r 110«

[0378] RN: 60444-78-2) HAJ 0

[0379] 0

[0380] Cy®3 Mono NHS

[0381] Ester - AYA -A / A

[0382] commercially a- available

[0383] (only used as the

[0384] hydrolysed form,

[0385] thus with a free

[0386] carboxylic acid).

[0387]

[0388] Aldehyde-modified donor strand

[0389] To a solution of DNA (10 nmol) in water (100 pL) was added 4-formylbenzoic acid NHS in DMF (50 mM, 100 pL), MeCN (100 pL), and TEA (0.75 pL). The mixture was shaken for 4 hours at rt. The DNA was precipitated by the addition of aq. NaOAc (3 M, 43 pL, pH = 5.2), cold EtOH (750 pL) and glycogen (1 pL, 20 mg / mL). The mixture was cooled in liq. N2 followed by centrifugation for 45 min (4 °C, 20000 g). The supernatant was removed, and the pellet redissolved in MQ and subsequently purified by RP-HPLC 10-20% MeCN in 0.1 M TEAA over 15 min. Flow = 1 mL / min. T = 25 °C. The product-containing fractions were collected and lyophilised.

[0390] Aldehyde modified donor strand: Rt = 8.9 min (47%) LC-MS(ESI): [M]; Calc.: 7499.2 found: 7494.4

[0391] Example 2 - Reductive amination on various antibodies or fragments thereof

[0392] Aim of study

[0393] The aim of this study is to determine the broadness of the method of employing the benzaldehyde-modified DNA for bioconjugation purposes and conjugation to different antibodies and fragments hereof.

[0394] Materials and methods83692PC01

[0395] 40

[0396] The general methods are described earlier, specific for this example is that the anti-dabigatran fab fragment (aDab) was bought as the antidote (Idarucizumab® a.k.a Praxbind®) from Boehringer Ingelheim. The remainder of the proteins were custom raised by the Danish Company BioPorto using mice and standard hybridoma technologies. It should be noted that all antibodies have been raised against small molecule targets.

[0397] Synthesis method

[0398] To the protein (X pM, 50-4000 pmol. 1 equiv.) is added the aldehyde-modified DNA strand (SEQ ID NO: 1) containing an internal fluorophore (Y equiv.), NaCNBHs (25 mM) in HEPES (pH 7.0 50 mM) and left to react overnight (ON) at room temperature (rt), omitting any light and with slight agitation of the sample.

[0399] A specific embodiment of the process of the invention is illustrated in Figure 1.

[0400] Purification

[0401] The resulting mixture was purified by HPLC.

[0402] Anion exchange was performed with a Thermo ScientificTM DionexTM DNAPacTM PA-100 4x250 mm column on a Hewlett Packard Agilent 1100 Series HPLC system.

[0403] The purification was performed with Buffer A (25 mM Tris, pH 8) and Buffer B (25 mM Tris pH 8, 1 M NaCI) with an increasing gradient of buffer B (0-75%) over 10 min (flow rate: 1 mL / min, T = 25 °C).

[0404] Determination of yield

[0405] The yield was determined by quantifying the integrals of the whole chromatogram of the FLD signal (fluorescence of tryptophan and tyrosine of the protein) and determining the percentage contained in the corresponding protein-DNA peaks (DAR=1, rt=8-9.3 min or DAR=2, rt=9.4-ll min).

[0406] Results

[0407] Table 3:

[0408] Protein Condition Yield

[0409]

[0410] 83692PC01

[0411] 41

[0412] Anti-Apixaban antibody X=20 pM, Y=1 42% DAR=1, 11% DAR=2 (Example 6) equiv., 20 pM

[0413] Anti-Apixaban antibody X=20 pM, Y=1 51% DAR=1, 12% DAR=2 (Rabbit based clone) equiv., 20 pM

[0414] (data not shown)

[0415] Anti-Rivaroxaban X=20 pM, Y=1 52% DAR=1, 13% DAR=2 antibody equiv., 20 pM

[0416] Anti-Dabigatran antibody X=7 pM, Y=2 26% DAR=1, 35% DAR=2

[0417] equiv., 14 pM

[0418] Anti-Dabigatran fab X=20 pM, Y=1 67% DAR=1, 0% DAR=2 fragment (Praxbind®)* equiv., 20 pM

[0419] Anti-Edoxaban antibody X=20 pM, Y=1 25% DAR=1, 56% DAR=2

[0420] equiv., 20 pM

[0421] Anti-Methotrexate X=7 pM, Y=2 11% DAR=1, 44% DAR=2 antibody equiv., 14 pM

[0422] Anti-Linezolid antibody **X=8 pM, Y=2 35% DAR=1, 6% DAR=2

[0423] equiv., 16 pM

[0424] X=8 pM, Y=5 47% DAR=1, 20% DAR=2 equiv., 40 pM

[0425]

[0426] *Yield calculated as the intensity of all signals of signal at 260 nm arising from the DNA strand (the aldehyde-modified DNA strand (rt=11.3 min)) versus signal arising from the protein-DNA conjugate (rt=9.8 min) due to the fact that the Fab eluded in the void volume of the column. Equiv: By moles.

[0427] **The conditions here where chosen to modulate the ratio between DAR=1 and DAR=2 product, and not to achieve the highest possible yield.

[0428] From Table 3, it is evident that a broad range of antibodies can be employed in the bioconjugation reaction. The yield of the most dominant product (either DAR=1 or Dar=2) ranges from 35%-67%, with the only other unwanted product being the other compound. Based on the results, it is also evident that the conditions can be tuned to select for the most wanted DAR. Under the presented conditions, there was no evidence of DAR=3 or other side reactions that consumed the protein.83692PC01

[0429] 42

[0430] It should be noted that only DAR=1 could be obtained on the fab fragment, which is hypothesised to be due to the relatively smaller size of the fragment where charge repulsion of DNA would play a more central role, as does the fact that fewer amines are present in the fragment.

[0431] It should be noted that the highest-yielding product of all the protein-DNA conjugates listed in Table 3 has been used for immunoassay development, exhibiting retained affinity towards their respective small molecule targets (data not shown).

[0432] Conclusion

[0433] The described method allowed efficient preparation of highly defined DNA-protein conjugates in an efficient manner. Satisfactorily yield ranging from 43% to 81% total yield with clearly defined DAR=1 and DAR=2, easily separated by ion exchange chromatography. The product was obtained on a range of proteins and fragments thereof, all of which retained affinity towards their small molecule binding partner.

[0434] In sum, the method of the invention can efficiently produce DAR=1 and DAR=2 protein-DNA conjugates for a range of proteins and fragments thereof.

[0435] For Fab fragments, only DAR=1 was obtained.

[0436] Example 3 - Dabigatran conjugation under various conditions

[0437] Aim of study

[0438] The aim of this study is to determine the impact of relevant molecules and conditions in the bioconjugation of a f(ab) fragment developed to bind dabigatran with an aldehyde-modified DNA strand containing a fluorophore in order to elucidate potential effects and mechanisms.

[0439] Materials and methods

[0440] The general methods are described earlier, specific for this example is that the anti-dabigatran fab fragment (aDab) was bought as the antidote (Idarucizumab® a.k.a Praxbind®) from Boehringer Ingelheim.

[0441] Synthesis method83692PC01

[0442] 43

[0443] To the protein (anti-dabigatran fab fragment) (20 pM, 50 pmol) is added the aldehyde-modified DNA strand (Entries 1-3, 5-16: SEQ ID NO: 1. Entry 4: SEQ ID NO: 2) (1 equiv., 20 pM), NaCNBH3(25 mM) in buffer (Entries 1-7: HEPES pH 7.0 50 mM. Entry 8: HEPES pH 7.5 50 mM. Entry 9: HEPES pH 8.0 50 mM. Entry 10: MES pH 5.5 50 mM. Entry 11: Phosphate pH 6.0 50 mM. Entry 12: Phosphate pH 6.2 50 mM. Entry 13: Phosphate pH 6.5 50 mM. Entry 14: PBS pH 7.4 lx. Entry 15: Borate pH 9.0 50 mM. Borate pH 9.5 50 mM.), salt (Entry 1, 4-16: None. Entry 2: 12.5 mM MgC . Entry 3: 500 mM NaCI), Dabigatran (Entry 1-4, 8-16: none. Entry 5: 0.5 equiv. Entry 6: 1 equiv. Entry 7: 2.5 equiv.) and left to react overnight (ON) at room temperature (rt), omitting any light and with slight agitation of the sample.

[0444] Entry refers to table entry in Table 4.

[0445] Purification

[0446] The resulting mixture was without further purification HPLC purified.

[0447] Anion exchange was performed with a Thermo ScientificTM DionexTM DNAPacTM PA-100 4x250 mm column on a Hewlett Packard Agilent 1100 Series HPLC system.

[0448] The purification was performed with Buffer A (25 mM Tris, pH 8) and Buffer B (25 mM Tris pH 8, 1 M NaCI) with an increasing gradient of buffer B (0-75%) over 10 min (flow rate: 1 mL / min, T = 25 °C).

[0449] Determination of yield

[0450] The yield was determined using the signal originating from DAD, monitoring the absorbance at 260 nm for DNA.

[0451] Results

[0452] Table 4:

[0453] Entry Conditions Deviations from protocol Yield (DAR=1) 1 HEPES pH 7.0 67%

[0454] 2 buffer 12.5 mM MgCh 28%

[0455] 3 500 mM NaCI 35%

[0456] 4 No Cy3 on DNA strand Less than 5%

[0457]

[0458] 83692PC01

[0459] 44

[0460] 5 Presence of Dabigatran 0.5 eq 25%

[0461] 6 Presence of Dabigatran 1.0 eq Less than 5% 7 Presence of Dabigatran 2.5 eq 0%

[0462] 8 pH 7.5 58%

[0463] 9 pH 8.0 41%

[0464] 10 MES pH 5.5 70%

[0465] buffer

[0466] 11 Phosphate pH 6.0 53%

[0467] 12 buffer pH 6.2 50%

[0468] 13 pH 6.5 51%

[0469] 14 PBS pH 7.4 34%

[0470] buffer

[0471] 15 Borate pH 9.0 21%

[0472] 16 buffer pH 9.5 8%

[0473]

[0474] From Table 4, it is evident that the bioconjugation reaction onto the fab fragment raised against dabigatran does experience the antagonising effect from the presence of NaCI or MgC (Entries 2, 3, and 14, compared to Entry 1), presumably due to the shielding of the charges of the DNA impairing any interaction of the protein with the DNA strand that would otherwise increase the conjugation yield.

[0475] It is likewise evident from Table 4 that the Cy3 moiety on the DNA strand does contribute to significant bioconjugation yield, as omission hereof reduces the yield drastically (Entry 4).

[0476] Additionally, the reaction also experiences an antagonising effect from the presence of the small molecule itself (Entries 5, 6, and 7), with a close to linear response in the range 0-1 equiv., implying that the occupation of the binding site of the protein greatly interferes with bioconjugation. This, in turn, implies some sort of guiding occurring towards the binding site.

[0477] Lastly, an increase in the pH does also decrease the yield, presumably due to the diminished reactivity of the benzaldehyde moiety at basic pH (Entries 8, 9, 15, and 16).

[0478] Conclusion83692PC01

[0479] 45

[0480] A range of conditions impact the bioconjugation reaction towards the anti-dabigatran fab. The presence of the small molecule (dabigatran) reduces bioconjugation yield to a point where no product is observed. The absence of Cy3 on the DNA strand reduces bioconjugation, likewise to a point where no product is observed. The presence of NaCI and MgC reduces bioconjugation yield, as does elevated pH levels (above pH 7), compared to neutral pH (pH 7).

[0481] Example 4 - Dabigatran conjugation with increased equivalents of aldehyde-modified DNA

[0482] Aim of study

[0483] The aim of this study is to determine the impact of increasing equivalents of an aldehyde-modified DNA strand containing a fluorophore on the bioconjugation of a f(ab) fragment developed to bind dabigatran.

[0484] Materials and methods

[0485] The general methods are described earlier. Specific for this example is that the anti-dabigatran fab fragment (aDab) was bought as the antidote (Idarucizumab® a.k.a Praxbind®) from Boehringer Ingelheim.

[0486] Synthesis method

[0487] To the protein (anti-dabigatran fab fragment) (20 pM, 50 pmol) is added the aldehyde modified DNA strand (SEQ ID NO: 1.) (1-5 equiv.), NaCNBHs (25 mM) in HEPES (pH 7.0 50 mM) and left to react overnight (ON) at room temperature (rt), omitting any light and with slight agitation of the sample.

[0488] Analysis

[0489] The resulting mixture was, without further purification, added SDS loading buffer and analysed by gel electrophoresis (45 min, 4°C, 200 V, SDS page 4-12%) and stained with Coomassie safe stain.

[0490] Determination of yield

[0491] The yield was determined using optical densitometry (OD) with the software Image J and relating the intra-band intensity of the protein DNA conjugate with the unmodified protein.83692PC01

[0492] 46

[0493] Results

[0494] Table 5:

[0495] Condition Relative intensity of protein-DNA conjugate 1 equiv. SEQ ID 1 22%

[0496] 2 equiv. SEQ ID 1 29%

[0497] 3 equiv. SEQ ID 1 35%

[0498] 5 equiv. SEQ ID 1 36%

[0499]

[0500] Based on Table 5, it is evident that increasing the aldehyde-modified DNA strand increases the yield of the bioconjugation reaction. However, in this analysis, no other product was observed, as only the intensity of the protein-DNA conjugate band did increase in OD. It is hypothesised that due to the relatively small size of the fab and the charge repulsion of the DNA strand, a negative cooperative effect of DNA is present preventing multiple DNA strands to conjugate.

[0501] Conclusion

[0502] The increased equivalency of benzaldehyde modified DNA did result in increased yield of the protein DNA conjugate, and only DAR=1 is evident.

[0503] Example 5 - Conjugation towards anti-Dabigatran fab in presence of Cy3 Aim of study

[0504] The aim of this study is to determine the impact of free Cy3 on the bioconjugation to the anti-dabigatran f(ab) fragment.

[0505] Materials and methods

[0506] The general methods are described earlier, specific for this example is that the anti-dabigatran fab fragment (aDab) was bought as the antidote (Idarucizumab® a.k.a Praxbind®) from Boehringer Ingelheim.

[0507] Cy®3 Mono NHS Ester was hydrolysed overnight in 1 x PBS prior to addition.

[0508] Synthesis method

[0509] To the protein (anti-dabigatran fab fragment) (20 pM, 50 pmol) is added the aldehyde-modified DNA strand (SEQ ID NO: 1) containing an internal fluorophore (1 equiv., 20 pM), NaCNBHs (25 mM), Hydrolyzed Cy3 (0 to 350 pM) in HEPES83692PC01

[0510] 47

[0511] (pH 7.0 50 mM) and left to react overnight (ON) at room temperature (rt), omitting any light and with slight agitation of the sample.

[0512] Purification

[0513] The resulting mixture was without further purification HPLC purified.

[0514] Anion exchange was performed with a Thermo ScientificTM DionexTM DNAPacTM PA-100 4x250 mm column on a Hewlett Packard Agilent 1100 Series HPLC system.

[0515] The purification was performed with Buffer A (25 mM Tris, pH 8) and Buffer B (25 mM Tris pH 8, 1 M NaCI) with an increasing gradient of buffer B (0-75%) over 10 min (flow rate: 1 mL / min, T = 25 °C).

[0516] Determination of effect in yield

[0517] The impact of the Cy3 was determined by relating the integral of the protein-DNA FLD peak on the chromatogram to the integrals of the same peak at varying Cy3 concentrations. This was done as Cy3 did adhere / stick to the aldehyde-modified DNA peak, thus making an intra-run ratiometric approach heavily biased.

[0518] Results

[0519] Table 6:

[0520] Condition Yield (DAR=1) compared to reference

[0521] 0 pM free Cy3 Reference - 100%

[0522] 50 pM free Cy3 72%

[0523] 200 pM freeCy3 49%

[0524] 350 pM free Cy3 42%

[0525]

[0526] From Table 6, it is evident that the bioconjugation reaction onto the fab fragment raised against dabigatran does experience an antagonising effect from the presence of free Cy3. This is in line with the findings of example 3, where the absence of Cy3 on the DNA strand resulted in a significant reduction of yield.

[0527] Conclusion

[0528] The presence of free Cy3 in the reaction mixture has an antagonistic effect on the yield. From the data, it is evident that the yield of protein-DNA conjugate drops to83692PC01

[0529] 48

[0530] only 42% compared to reference in the presence of 350 pM Cy3, which, together with example 3, highlights the importance of Cy3 in the reaction towards the fab.

[0531] Example 6 - Full antibody against apixaban conjugation to aldehyde-modified DNA under various conditions

[0532] Aim of study

[0533] The aim of this study is to determine the impact of relevant molecules that impact the bioconjugation of a full antibody developed to bind apixaban with an aldehyde-modified DNA strand containing a fluorophore in order to elucidate potential effects and mechanisms.

[0534] Materials and methods

[0535] The general methods are described earlier, specific for this example is the use of the anti-apixaban full antibody (aAPX) that was custom raised by the Danish Company BioPorto using mice and standard hybridoma technologies.

[0536] Synthesis method

[0537] The full antibodies were, prior to conjugation, washed with HEPES pH 8.0 10 mM buffer thrice in Amicon Ultra® centrifugal filters (MWCO 3K, 14100 g for 30 min) to remove the buffer components interfering in the reductive amination.

[0538] To the protein (anti-apixaban antibody) (20 pM, 50 pmol) is added the aldehyde modified DNA strand (Entry 1, 3, 4, 5: SEQ ID NO: 1. Entry 2, SEQ ID NO: 2) (1 equiv., 20 pM), NaCNBH3(25 mM) in HEPES (pH 7.0 50 mM), Free Cy3 Fluorophore (Entry 1, 2, 3, 5: none. Entry 4: 250 pM), Apixaban (Entry 1, 2, 4, 5: none. Entry 3: 2.5 equiv), Salt (Entry 1, 2, 3, 4: None. Entry 5: 50 mM MgC ) and left to react overnight (ON) at room temperature (rt), omitting any light and with slight agitation of the sample.

[0539] Entry 4 was hereafter washed with PBS lx buffer thrice in Amicon Ultra® centrifugal filters (MWCO 3K, 14100 g for 30 min) to remove excess Cy3 prior to HPLC analysis.

[0540] Purification

[0541] The resulting mixture was without further purification HPLC purified.83692PC01

[0542] 49

[0543] Anion exchange was performed with a Thermo ScientificTM DionexTM DNAPacTM PA-100 4x250 mm column on a Hewlett Packard Agilent 1100 Series HPLC system.

[0544] The purification was performed with Buffer A (25 mM Tris, pH 8) and Buffer B (25 mM Tris pH 8, 1 M NaCI) with an increasing gradient of buffer B (0-75%) over 10 min (flow rate: 1 mL / min, T = 25 °C).

[0545] Determination of yield

[0546] The yield was determined using the signal originating from the FLD, fluorescence of tryptophan and tyrosine of the protein. Here either the ratio of the unmodified protein (rt=5.1min), versus the monolabelled (rt=8.5 min, DAR=1) or double labelled (rt=9.4 min, DAR=2). The yield is the combined signal of the mono and double-labelled products compared to the unmodified.

[0547] Results

[0548] Table 7:

[0549] Entry Condition Deviations Yield Monolabel Buffer PH from protocol (%) yield (%) 1 HEPES pH 7.0 53% 42%

[0550] 2 buffer No Cy3 on DNA 51% 43%

[0551] strand

[0552] 3 Presence of 70% 52%

[0553] Apixaban 2.5 eq

[0554] 4 Presence of free 47% 37%

[0555] Cy3

[0556] 5 50 mM MgCb 23% 20%

[0557]

[0558] From Table 7, it is evident that the bioconjugation reaction onto the full antibody raised against apixaban does experience an antagonising effect from the presence of the MgC , presumable due to the shielding of the charges of the DNA impairing any interaction of the protein with the DNA strand that would otherwise increase the conjugation yield. Interestingly, the presence of 2.5 eq apixaban small molecule does increase conjugation yield, thus providing hints that the binding site itself might antagonise the reaction, possibly by actively scavenging83692PC01

[0559] 50

[0560] reactants. The influence of Cy3 shows to impair the effect shown in example 3 and example 4, such as the fluorophore on the DNA strand as well as free Cy3, does only seem to decrease the yield insignificantly at the presented reaction conditions.

[0561] Therefore, under more diluted conditions, another experiment was made.

[0562] To the protein (anti-apixaban antibody) (7 pM, 50 pmol) is added the aldehyde-modified DNA strand (Entry 1: SEQ ID NO: 1. Entry 2: SEQ ID NO: 2) (2 equiv., 14 pM), NaCNBH3(25 mM) in HEPES (pH 7.0 50 mM), F and left to react overnight (ON) at room temperature (rt), omitting any light and with slight agitation of the sample. The resulting mixture was hereafter analysed by a gel electrophoretic analysis using an SDS-PAGE 4-12% gel and stained by Coomassie safe stain. Using OD and image J analysis software, the following yield was obtained based on the optical densitometric response of the corresponding bands.

[0563] Table 8

[0564] Entry Condition Yield (%)

[0565] 1 SEQ ID NO: 1 44%

[0566] 2 SEQ ID NO: 2 24%

[0567]

[0568] From the results in Table 8, it is evident that the cy3 on the DNA strand does contribute to increased yield when the reaction conditions are dilute enough.

[0569] Conclusion

[0570] It was found that salt did decrease the yield of the reaction significantly, with overall yields dropping from 53% to 23% in the presence of 50 mM MgC .

[0571] Initially, it was found that free Cy3 did not decrease reaction yield or that omission of Cy3 on the DNA strand led to decreased reaction yield.

[0572] It was shown in another experiment that more dilute reaction conditions indeed showed the impact of Cy3 on the DNA strand with almost a factor two difference in yield comparing the presence or absence of the Cy3 on the DNA strand (44% vs 24%).83692PC01

[0573] 51

[0574] Example 7 - Full antibody against rivaroxaban conjugation to aldehyde-modified DNA at different pH and salt concentrations.

[0575] Aim of study

[0576] The aim of this study is to determine the impact of pH and salt on the bioconjugation of a full antibody developed to bind rivaroxaban an aldehyde-modified DNA strand containing a fluorophore in order to elucidate potential effects and mechanisms.

[0577] Materials and methods

[0578] The general methods are described earlier. Specific for this example is the use of the anti-rivaroxaban full antibody (aRIV) that was custom raised by the Danish Company BioPorto using mice and standard hybridoma technologies.

[0579] Synthesis method

[0580] The full antibody was, prior to conjugation, washed with HEPES pH 8.0 10 mM buffer thrice in Amicon Ultra® centrifugal filters (MWCO 3K, 14100 g for 30 min) to remove the buffer components interfering in the reductive amination.

[0581] To the protein (anti-rivaroxaban antibody) (20 pM, 50 pmol) is added the aldehyde modified DNA strand (SEQ ID NO: 1) containing an internal fluorophore (1 equiv., 20 pM), NaCNBHs (25 mM) in buffer (Entry 1: MES pH 5.5 50 mM. Entry 2: Phosphate pH 6.0 50 mM. Entry 3: Phosphate pH 6.5 50 mM. Entry 4-6: HEPES pH 7.0 50 mM. Entry 7: PBS pH 7.4 lx. Entry 8: HEPES pH 7.5 50 mM. Entry 9: HEPES pH 8.0 50 mM. Entry 10: Borate pH 8.5 50 mM. Entry 11: Borate pH 9.0 50 mM. Entry 12: Borate pH 9.5 50 mM.), Salt (Entry 1-4, 7-12: none. Entry 5: 500 mM NaCI. Entry 6: 12.5 mM MgC ) and left to react overnight (ON) at room temperature (rt), omitting any light and with slight agitation of the sample.

[0582] Purification

[0583] The resulting mixture was without further purification HPLC purified.

[0584] Anion exchange was performed with a Thermo ScientificTM DionexTM DNAPacTM PA-100 4x250 mm column on a Hewlett Packard Agilent 1100 Series HPLC system.83692PC01

[0585] 52

[0586] The purification was performed with Buffer A (25 mM Tris, pH 8) and Buffer B (25 mM Tris pH 8, 1 M NaCI) with an increasing gradient of buffer B (0-75%) over 10 min (flow rate: 1 mL / min, T = 25 °C).

[0587] Determination of yield

[0588] The yield was determined using the signal originating from the FLD, fluorescence of tryptophan and tyrosine of the protein, being the ratio of the unmodified protein (rt=5.1min), monolabelled (rt=8.5 min, DAR=1) and double labelled (rt=9.4 min, DAR=2).

[0589] Results

[0590] Table 9:

[0591] Entry Conditions Additive Yield % Yield (DAR=1) % Buffer PH

[0592] 1 MES buffer pH 5.5 66% 50%

[0593] 2 Phosphate pH 6.0 59% 47%

[0594] 3 buffer pH 6.5 48% 41%

[0595] 4 HEPES pH 7.0 65% 52%

[0596] 5 buffer 500 mM NaCI 22% 19%

[0597] 6 12.5 mM MgCh 32% 20%

[0598] 7 PBS buffer pH 7.4 50% 42%

[0599] 8 HEPES pH 7.5 60% 49%

[0600] 9 buffer pH 8.0 58% 48%

[0601] 10 Borate pH 8.5 56% 47%

[0602] 11 buffer pH 9.0 51% 43%

[0603] 12 pH 9.5 33% 29%

[0604]

[0605] From Table 9, it was observed that the bioconjugation reaction onto the full antibody raised against rivaroxaban is mildly affected by the pH, similar to Examples 3 and 6. The formation of labelled protein favours neutral pH, while a strong increase in pH leads to lower conversion, presumably due to diminished benzaldehyde reactivity in reductive amination reaction. Furthermore, the reaction does experience a strong antagonising effect from the additional presence of the NaCI and MgC (Entries 5 and 6, respectively), as well as a milder effect in83692PC01

[0606] 53

[0607] phosphate and PBS buffers (Entries 3 and 7, respectively). This is presumably due to the shielding of the charges of the DNA impairing any interaction of the protein with the DNA strand that would otherwise increase the conjugation yield.

[0608] It was hypothesised that by decreasing reaction concentration by dilution, one could further see an increase of the impact of salt in the bioconjugation reaction.

[0609] Conclusion

[0610] In the presented conditions screen of conjugation towards rivaroxaban, it is shown that the presence of salt, either PBS buffer or 500 mM NaCI, reduced conjugation yield, as did the presence of 12.5 mM MgC .

[0611] Example 8 -Genericity of the process on all tested clones.

[0612] Aim of study

[0613] The aim of this experiment is to show the genericity of the bioconjugation concept on a range of clones developed toward their respective small molecule targets.

[0614] Materials and methods

[0615] The general method is described earlier, specific for this example is the use of all the clones raised against their respective small molecule showing affinity in a standard ELISA screen custom raised by the Danish Company BioPorto using mice and standard hybridoma technologies.

[0616] Synthesis method

[0617] The full antibodies were prior to conjugation washed with HEPES pH 8.0 10 mM buffer thrice in Amicon Ultra® centrifugal filters (MWCO 3K, 14100 g for 30 min) to remove the buffer components interfering in the reductive amination.

[0618] To the protein (conditions listed in the Table 3 in example 2.) is added the aldehyde-modified DNA strand (SEQ ID NO: 1) containing an internal fluorophore (conditions listed in Table 2 in example 1), NaCNBHs (25 mM) in HEPES (pH 7.0 50 mM) and left to react overnight (ON) at room temperature (rt), omitting any light and with slight agitation of the sample.

[0619] Purification

[0620] The resulting mixture was without further purification HPLC purified.83692PC01

[0621] 54

[0622] Anion exchange was performed with a Thermo ScientificTM DionexTM DNAPacTM PA-100 4x250 mm column on a Hewlett Packard Agilent 1100 Series HPLC system.

[0623] The purification was performed with Buffer A (25 mM Tris, pH 8) and Buffer B (25 mM Tris pH 8, 1 M NaCI) with an increasing gradient of buffer B (0-75%) over 10 min (flow rate: 1 mL / min, T = 25 °C).

[0624] Results

[0625] Table 10:

[0626] Antibody Isolated protein-DNA Comment

[0627] target conjugate out of clones

[0628] available.

[0629] Methotrexate 8 out of 8

[0630] Dabigatran full 4 out of 4

[0631] antibody

[0632] Rivaroxaban 7 out of 7

[0633] Edoxaban 2 out of 4

[0634] Linezolid 1 out of 1 Best binder already identified prior to bioconjugate screening Dabigatran fab 1 out of 1 Only 1 fab fragment fragment available.

[0635] Apixaban 2 out of 2 Best 2 binders already identified prior to bioconjugate screening.

[0636]

[0637] From Table 10, it is evident that the method for bioconjugation efficiently yields DNA-modified proteins, with the only outlier being the antibody clones against edoxaban, which is, however, still considered very efficient. The qualifier for a successful bioconjugation is that a sufficient amount could be isolated to test downstream for immunoassay purposes.

[0638] The overview of one of these screens is shown in Table 11 below, with isolated yields of DAR=1 ranking from 27-39%. All antibodies conjugated under these83692PC01

[0639] 55

[0640] conditions, however, Antibody 23 did not result in a clean HPLC, albeit an overall yield of 51%, but not easily categorised as either mono or double labelled, indicating degradation, aggregation or other during the reaction conditions.

[0641] Table 11:

[0642] Riv targeting antibody Yield Yield of DAR=1

[0643] 1 45% 27%

[0644] 2 51% 36%

[0645] 14 65% 29%

[0646] 20 43% 39%

[0647] 22 46% 29%

[0648] 23 51% n / a

[0649] 31 53% 24%

[0650]

[0651] From Table 11, satisfactory conversion for all antibodies was seen, with only 1 (clone 23) indicating clone-specific instability (degradation or aggregation) during the reaction. The primary products are mono labelled and double-labelled.

[0652] Conclusion

[0653] In conclusion, 25 out of 27 clones (93%) yielded products based on the presented method which is a very successful outcome within bioconjugation. Even the 50% efficiency for Edoxaban, albeit not as successful as the other protein conjugations, is considered satisfactory. The presented screening for rivaroxaban did likewise show the genericity of the approach, as all clones did yield in the range 43-65%.

[0654] Example 9 -Genericity of the process on non-IgG proteins.

[0655] Aim of study

[0656] The aim of this experiment is to show the genericity of the bioconjugation concept on a range of proteins that are not of the immunoglobulin family, including analyte-binding protein Factor Xa.

[0657] Materials and methods

[0658] The general method is described earlier, specific for this example is the use of various proteins purchased from Sigma Aldrich.83692PC01

[0659] 56

[0660] Synthesis method

[0661] To the protein (conditions listed in Table 3 in example 2. Entry 1: Lysozyme. Entry 2: Factor Xa. Entry 3: Transferrin) is added the aldehyde modified DNA strand (SEQ ID NO: 1) containing an internal fluorophore (conditions listed in Table 2 in example 1), NaCNBHs (25 mM) in HEPES (pH 7.0 50 mM) and left to react overnight (ON) at room temperature (rt), omitting any light and with slight agitation of the sample.

[0662] Determination of conversion

[0663] The resulting mixture was, without further purification, analysed by native PAGE using NuPAGE precast gels from Thermo Fisher Scientific. The samples were prepared with OrangeG DNA loading dye (6x) and loaded onto 4-20% TBE PAGE gel. The samples were eluted for 45 min at 200 V in TBE (lx) buffer. After elution, the gel was stained by Coomassie SimplyBlue™ SafeStain. The yield of DAR = 1 was calculated based on the band intensity ratio of unmodified and modified protein.

[0664] Results

[0665] Table 12:

[0666] Size Yield of Entry Protein Theoretical pl

[0667] (kDa) DAR =1 1 Lysozyme 15 9.36 41%

[0668] 2 Factor Xa 39 5.68 17%

[0669] 3 Transferrin 76 8.61 29%

[0670]

[0671] Theoretical pl values were calculated using information from web.expasy.org. From Table 12, all proteins indicated a formation of DNA-modified protein. Of them, 2 proteins with the highest pl values - lysozyme (Entry 1) and transferrin (Entry 3) - showed a distinct conversion of bioconjugation reaction. Without being bound by a theory, it is believed that the strong positive charge of the protein (described by the pl value) provides adherence to the negatively charged singlestranded DNA under low salt concentration (low ionic strength). In another experiment, the presence of salt caused an antagonising effect on the bioconjugation of transferrin, similar to Examples 3, 6, and 7.83692PC01

[0672] 57

[0673] Additionally, the antigen-binding protein factor Xa (Entry 2) also demonstrated the formation of a DNA-modified product. Again, without being bound by theory, it is considered that, like antibodies, the antigen-binding proteins can interact with a Cy3 modification on the DNA strand to improve the coupling efficiency.

[0674] Conclusion

[0675] In the presented protein screen of conjugation, it is shown that highly positively charged proteins and antigen-binding protein Factor Xa can be labelled via the bioconjugation reaction due to the interaction with the DNA strand.

[0676] Example 10 -Antibody Fab against apixaban conjugation to aldehyde-modified DNA with different reducing agents.

[0677] Aim of study

[0678] The aim of this study is to determine the impact of the reducing agent on the bioconjugation of an antibody Fab fragment developed to bind apixaban an aldehyde-modified DNA strand containing a fluorophore. Additionally, NaCNBHs is associated with safety concerns due to cyanide release, therefore, a safer alternative is investigated, namely, 2-Methylpyridine borane complex.

[0679] Materials and methods

[0680] The general methods are described earlier. Specific for this example is the use of the anti-apixaban antibody Fab (aApx) that was custom raised by the company GenScript in rabbits and then recombinantly expressed in Chinese hamster ovary (CHO) cell line, and the use of reducing agents: NaCNBHs and 2-Methylpyridine borane complex.

[0681] Synthesis method

[0682] To the protein (conditions listed in Table 3 in example 2) is added the aldehyde modified DNA strand (SEQ ID NO: 1) containing an internal fluorophore (conditions listed in Table 2 in example 1), reducing agent (Entry 1: NaCNBHs, Entry 2: 2-methylpyridine borane complex in 5% DMSO, Entry 3: No reducing agent) (25 mM) in HEPES (pH 7.0 50 mM and left to react overnight (ON) at room temperature (rt), omitting any light and with slight agitation of the sample.

[0683] The reactions were performed in 50 mM HEPES buffer pH 7.0 with no additional salt.

[0684] Purification83692PC01

[0685] 58

[0686] The resulting mixture was without further purification HPLC purified.

[0687] Anion exchange was performed with a Thermo ScientificTM DionexTM DNAPacTM PA-100 4x250 mm column on a Hewlett Packard Agilent 1100 Series HPLC system.

[0688] The purification was performed with Buffer A (25 mM Tris, pH 8) and Buffer B (25 mM Tris pH 8, 1 M NaCI) with an increasing gradient of buffer B (0-75%) over 10 min (flow rate: 1 mL / min, T = 25 °C).

[0689] Determination of yield

[0690] The yield was determined using the signal originating from the FLD, fluorescence of tryptophan and tyrosine of the protein, being the ratio of the unmodified protein (rt=2.4 min) and monolabelled (rt=9.1 min, DAR=1).

[0691] Results

[0692] Table 13:

[0693] Entry Reducing agent Yield of DAR = 1

[0694] 1 NaCNBH332%

[0695] 2 2-Methylpyridine borane complex 44%

[0696] 3 No reducing agent <1%

[0697]

[0698] From Table 13, it is observed that the bioconjugation works broadly for reducing agents designed for reductive amination - NaCNBHs (Entry 1) and even better with its safer alternative 2-Methylpyridine borane complex (Entry 2).

[0699] Large-scale synthesis

[0700] The synthesis was repeated for conditions in Entry 1 and Entry 2 on a 20-nmol scale, following the protocol described earlier. After purification, the conjugate (DAR=1) was isolated and quantified based on Cy3 absorbance (553 nm, 136000 M’^cm’1). The bioconjugation afforded the product in 32% isolated yield for with NaCNBHs (Entry 1) and 53% for 2-Methylpyridine borane complex (Entry 2).

[0701] Conclusion

[0702] The bioconjugation favors reducing agents that are selective for reductive amination, affording the conjugate in up to 53% isolated yield. Compared to the widely-used NaCNBHs, a safer, cyanide-free alternative of 2-Methylpyridine borane complex provides the highest conversion towards the conjugate.

Claims

83692PC0159Claims1. A process for preparing a protein-polymer conjugate (1), the process comprising the steps of:a) providing a protein (2), preferably an antibody or fragment thereof; b) providing a polymer (3), preferably a polyelectrolyte, more preferably an oligonucleotide, and even more preferably a DNA oligonucleotide, the polymer comprisingi. an aldehyde moiety (4), preferably being a 4-formylbenzoate moiety; andc) mixing the protein (2) from step a) with the polymer (3) from step b) in the presence of a reducing agent, preferably 2-Methylpyridine borane complex or NaCNBHs, and wherein the total salt concentration in the mixture is below 250 mM;d) incubating the mixture from step c), such as for at least 5 minutes at a temperature in the range of 3-45°C; ande) providing a composition comprising covalently linked protein-polymer conjugates (1).

2. The process according to claim 1, wherein the protein (2) is the target for a small molecule and / or has affinity for a small molecule.

3. The process according to claim 2, wherein the protein, preferably an antibody or fragment thereof, is specific for or has affinity for a small molecule selected from the group consisting of Rivaroxaban, Apixaban, and Dabigatran or anticoagulants such as Warfarin, Edoxaban, Rivaroxaban and Betrixaban, and immunosuppressants such as Methotrexate, Cyclosporine, Tacrolimus, Sirolimus, and Everolimus, and illegal drugs such as Cannaboids, Cocaine, Opiates (Heroin), Methamphetamine, Amphetamine, and Phencyclidine.

4. The process according to any of the preceding claims, wherein the polymer is an oligonucleotide, preferably a DNA oligonucleotide.

5. The process according to claim 2, wherein the small molecule has a size below or equal to 900 Daltons, such as in the range 100-900, 200-900, 300-900, 430-900 or 500-900 Daltons.83692PC01606. The process according to any of the preceding claims, wherein the polymer (3) is an oligonucleotide comprising a nucleotide comprising a modified moiety (5), such as a Cy3 moiety.

7. The process according to any of the preceding claims, wherein the protein is an antibody or fragment thereof having affinity for Dabigatran or Apixaban and the modified moiety (5) is Cy3.

8. The process according to any of the preceding claims, wherein the aldehyde modification is a 4-formylbenzoate moiety.

9. The process according to any of the preceding claims, wherein the reducing agent is 2-Methylpyridine borane complex or sodium cyanoborohydride (NaCNBHs), preferably 2-Methylpyridine borane complex or derivatives thereof, such as Pyridine borane, 3-Methylpyridine borane, 4-Methylpyridine borane, 2-Ethylpyridine borane, 2-n-Propylpyridine borane, 3-Ethylpyridine borane, 4-Ethylpyridine borane, 2,3-Lutidine borane, 2,6-Lutidine borane, 2,4,6-Collidine borane, 5-Ethyl-2-methylpyridine borane.

10. The process according to any of the preceding claims, wherein step c) and / or step d) is performed in a total salt concentration equal to or below 150 mM, more preferably equal to or below lOOmM, and even more preferably equal to or below 50 mM, such as equal to or below 10 mM or being free or substantially free of salt.

11. The process according to any of the preceding claims, wherein in step c) and / or step d), the mixture comprises salt in the range:• monovalent cations below 150 mM and being free or substantially free of divalent and trivalent cations; or• divalent cations below 20 mM and being free or substantially free of monovalent and trivalent cations; or• trivalent cations below 2 mM and being free or substantially free of monovalent and divalent cations.83692PC016112. The process according to claim 11, whereinmonovalent cations are selected from the group consisting of Sodium (Na+) Potassium (K+) and Ammonium (NH4+);- divalent cations are selected from the group consisting of Calcium (Ca2+), Magnesium (Mg2+), and Zinc (Zn2+); andtrivalent cations are selected from the group consisting of Ferric (Fe3+) and Aluminum (Al3+).

13. The process according to any of the preceding claims, wherein the protein is a Fab fragment; and in step e) the provided protein-polymer conjugates (1) have at least 70% conjugates having at the most one polymer (3) per protein, preferably at least 80% conjugates and more preferably at least 90% conjugates and even more preferably at least 95% of the conjugates have at the most one polymer (3) per protein.

14. The process according to any of the preceding claims, wherein the reducing agent is water soluble or aqueous-compatible.

15. The process according to any of the preceding claims, wherein step c) and / or d) is performed in the absence of an oligonucleotide able to hybridise to the polymer (3) from step b), such as the polymer being an oligonucleotide.

16. The process according to any of the preceding claims, wherein step c) and / or d) is performed in the absence of a second oligonucleotide able to hybridise to the oligonucleotide (3) from step b), with the proviso that the polymer is an oligonucleotide.

17. The process according to any of the preceding claims, wherein in step c) and / or step d) the pH is in the range 4-8.5, such as 5-8, preferably in the range 6-7.3.

18. The process according to any of the preceding claims, wherein in step c) and / or step d) the pH is in the range 4-7.3, such as 4-7, 4-6.5, 4-6, 5-7, or 5-6.83692PC016219. The process according to any of the preceding claims wherein step c) and / or d) is performed in a total salt concentration equal to or below 50 mM.

20. The process according to any of the preceding claims wherein step c) and / or d) is performed in a total salt concentration equal to or below 10 mM or being free or substantially free of salt, such as NaCI.

21. The process according to any of the preceding claims, wherein the protein (2) is not a metal-binding protein.

22. The process according to any of the preceding claims, wherein the protein (2) is an antibody or fragment thereof.